[{"id":"nct06503146","name":"18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection","tldr":"A phase 2 trial in pancreatic cancer, run by National Cancer Institute (NCI), now recruiting.","route":"/trials/nct06503146/","status":"recruiting","kind":"trial","cancerIcon":"pancreatic","sub":"NCT06503146","facets":{"kind":["Trial"],"cancers":["Pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07043270","name":"24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC","tldr":"A phase 2 trial of gemcitabine + nab-paclitaxel and fOLFIRINOX / mFOLFIRINOX in pancreatic cancer, run by Dartmouth-Hitchcock Medical Center, now recruiting.","route":"/trials/nct07043270/","status":"recruiting","kind":"trial","cancerIcon":"borderline-resectable-pdac","sub":"NCT07043270","facets":{"kind":["Trial"],"cancers":["Borderline resectable pancreatic ductal adenocarcinoma","Resectable pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Borderline resectable pancreatic ductal adenocarcinoma","href":"/cancers/borderline-resectable-pdac/","tip":"Borderline resectable pancreatic cancer touches the big blood vessels behind the pancreas, so an operation straight away would probably leave cancer behind. Chemotherapy first, usually FOLFIRINOX for several months and sometimes radiotherapy, shrinks the edge of the tumour, and patients whose disease has not spread go on to surgery with a better chance of a clean removal."},{"label":"Resectable pancreatic ductal adenocarcinoma","href":"/cancers/resectable-pdac/","tip":"Resectable pancreatic cancer is the minority of pancreatic cancer that the surgeon can remove with clear margins because it has not wrapped around the main arteries or spread. Treatment is an operation, usually a Whipple procedure, followed by six months of combination chemotherapy, which is what turns surgery alone into a real chance of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07578337","name":"A Clinical Study Evaluating a New Treatment Strategy for Patients With Advanced Pancreatic Cancer Who Have Not Received Prior Treatment for Advanced Disease.","tldr":"A phase 2 trial of gemcitabine, nab-paclitaxel and botensilimab in pancreatic cancer, run by Nelum Corp, not yet recruiting.","route":"/trials/nct07578337/","status":"planned","kind":"trial","cancerIcon":"metastatic-pdac","sub":"NCT07578337","facets":{"kind":["Trial"],"cancers":["Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07333287","name":"A Multicenter Single-arm Prospective Clinical Study on First-line Treatment of Pancreatic Cancer Liver Metastases With Arterial Infusion Chemotherapy and Emboli","tldr":"A phase 2 trial in pancreatic cancer, run by Shandong Provincial Hospital, not yet recruiting.","route":"/trials/nct07333287/","status":"planned","kind":"trial","cancerIcon":"locally-advanced-pdac","sub":"NCT07333287","facets":{"kind":["Trial"],"cancers":["Locally advanced unresectable pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07814066","name":"A Multicenter, Open-label, Phase II Umbrella Study to Evaluate the Efficacy and Safety of the Investigational Product in Participants With Advanced or Metastati","tldr":"A phase 2 trial in pancreatic cancer, run by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., not yet recruiting.","route":"/trials/nct07814066/","status":"planned","kind":"trial","cancerIcon":"metastatic-pdac","sub":"NCT07814066","facets":{"kind":["Trial"],"cancers":["Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07736612","name":"A Pan-RAS Inhibitor in Combination With Anti-Tumor Therapy in Participants With Advanced Pancreatic Cancer","tldr":"A phase 1/2 trial of nimotuzumab, HS-20093 and adebrelimab in pancreatic cancer, run by Zhejiang University, not yet recruiting.","route":"/trials/nct07736612/","status":"planned","kind":"trial","cancerIcon":"locally-advanced-pdac","sub":"NCT07736612","facets":{"kind":["Trial"],"cancers":["Locally advanced unresectable pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04381130","name":"A Phase I/IIa Study of EF-009 in Patients With Pancreatic Cancer","tldr":"A phase 1/2 trial in pancreatic cancer, run by Everfront Biotech Co., Ltd., not yet recruiting.","route":"/trials/nct04381130/","status":"planned","kind":"trial","cancerIcon":"pancreatic","sub":"NCT04381130","facets":{"kind":["Trial"],"cancers":["Pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07040228","name":"A Phase Ib/II Clinical Study of Regorafenib Combined With Toripalimab and Albumin-bound Paclitaxel for the Third-line Treatment of Advanced Pancreatic Cancer","tldr":"A phase 1/2 trial of regorafenib and toripalimab in pancreatic cancer, run by Junjie Hang, now recruiting.","route":"/trials/nct07040228/","status":"recruiting","kind":"trial","cancerIcon":"locally-advanced-pdac","sub":"NCT07040228","facets":{"kind":["Trial"],"cancers":["Locally advanced unresectable pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07233850","name":"A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers","tldr":"A phase 2 trial of SSGJ-706, cAPOX (capecitabine, oxaliplatin) and bevacizumab in pancreatic cancer, run by Shenyang Sunshine Pharmaceutical Co., LTD., not yet recruiting.","route":"/trials/nct07233850/","status":"planned","kind":"trial","cancerIcon":"resectable-pdac","sub":"NCT07233850","facets":{"kind":["Trial"],"cancers":["Resectable pancreatic ductal adenocarcinoma","Locally advanced unresectable pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Resectable pancreatic ductal adenocarcinoma","href":"/cancers/resectable-pdac/","tip":"Resectable pancreatic cancer is the minority of pancreatic cancer that the surgeon can remove with clear margins because it has not wrapped around the main arteries or spread. Treatment is an operation, usually a Whipple procedure, followed by six months of combination chemotherapy, which is what turns surgery alone into a real chance of cure."},{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07301229","name":"A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Pancreatic Cancer","tldr":"A phase 2 trial in pancreatic cancer, run by Shanghai Henlius Biotech, not yet recruiting.","route":"/trials/nct07301229/","status":"planned","kind":"trial","cancerIcon":"locally-advanced-pdac","sub":"NCT07301229","facets":{"kind":["Trial"],"cancers":["Locally advanced unresectable pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06906562","name":"A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic","tldr":"A phase 2 trial of pemigatinib in pancreatic cancer, run by Sameek Roychowdhury, now recruiting.","route":"/trials/nct06906562/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-pdac","sub":"NCT06906562","facets":{"kind":["Trial"],"cancers":["Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07283705","name":"A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer","tldr":"A phase 2 trial of navlimetostat, gemcitabine, nab-paclitaxel and fOLFIRINOX / mFOLFIRINOX in pancreatic cancer, run by M.D. Anderson Cancer Center, now recruiting.","route":"/trials/nct07283705/","status":"recruiting","kind":"trial","cancerIcon":"pancreatic","sub":"NCT07283705","facets":{"kind":["Trial"],"cancers":["Pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07784374","name":"A Phase II Study of GFH375 Combined With GFS202A or GFH276 Versus GFH375 Monotherapy in Patients With Previously Treated Locally Advanced Unresectable or Metast","tldr":"A phase 2 trial of GFH375 in pancreatic cancer, run by Genfleet Therapeutics (Shanghai) Inc., not yet recruiting.","route":"/trials/nct07784374/","status":"planned","kind":"trial","cancerIcon":"locally-advanced-pdac","sub":"NCT07784374","facets":{"kind":["Trial"],"cancers":["Locally advanced unresectable pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07438106","name":"A Phase II Study of HRS-4642 Combined With AG (Nab-paclitaxel and Gemcitabine) as Conversion Therapy for Locally Advanced Pancreatic Cancer","tldr":"A phase 2 trial in pancreatic cancer, run by The First Affiliated Hospital with Nanjing Medical University, now recruiting.","route":"/trials/nct07438106/","status":"recruiting","kind":"trial","cancerIcon":"locally-advanced-pdac","sub":"NCT07438106","facets":{"kind":["Trial"],"cancers":["Locally advanced unresectable pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06329947","name":"A Phase II Study of Surufatinib Combined With Camrelizumab and mFOLFOX6 as Second-line Treatment for Advanced PRAD","tldr":"A phase 2 trial in pancreatic cancer, run by Rui-hua Xu, MD, PhD, not yet recruiting.","route":"/trials/nct06329947/","status":"planned","kind":"trial","cancerIcon":"metastatic-pdac","sub":"NCT06329947","facets":{"kind":["Trial"],"cancers":["Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03301805","name":"A Phase II, EvaluateBLEX 404 Combined With Gemcitabine Monotherapy With Pancreatic Cancer","tldr":"A phase 2 trial in pancreatic cancer, run by Rgene Corporation, not yet recruiting.","route":"/trials/nct03301805/","status":"planned","kind":"trial","cancerIcon":"resectable-pdac","sub":"NCT03301805","facets":{"kind":["Trial"],"cancers":["Resectable pancreatic ductal adenocarcinoma","Locally advanced unresectable pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Resectable pancreatic ductal adenocarcinoma","href":"/cancers/resectable-pdac/","tip":"Resectable pancreatic cancer is the minority of pancreatic cancer that the surgeon can remove with clear margins because it has not wrapped around the main arteries or spread. Treatment is an operation, usually a Whipple procedure, followed by six months of combination chemotherapy, which is what turns surgery alone into a real chance of cure."},{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07336953","name":"A Phase III, Randomized, Clinical Trial of GnP Combined With SBRT and Serplulimab Versus GnP as First-Line Treatment for Patients With Recurrent or Metastatic P","tldr":"A phase 3 trial of gemcitabine + nab-paclitaxel and serplulimab in pancreatic cancer, run by West China Hospital, not yet recruiting.","route":"/trials/nct07336953/","status":"planned","kind":"trial","cancerIcon":"locally-advanced-pdac","sub":"NCT07336953","facets":{"kind":["Trial"],"cancers":["Locally advanced unresectable pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07689955","name":"A Phase-II Clinical Trial of Radiotherapy to the Coeliac Plexus to Help Pain in Advanced Pancreatic Cancer","tldr":"A phase 2 trial in pancreatic cancer, run by Royal Marsden NHS Foundation Trust, not yet recruiting.","route":"/trials/nct07689955/","status":"planned","kind":"trial","cancerIcon":"metastatic-pdac","sub":"NCT07689955","facets":{"kind":["Trial"],"cancers":["Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06866977","name":"A Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of VRT106 in Combination With Chemotherapy for Advanced Pancreatic Cancer","tldr":"A phase 1/2 trial in pancreatic cancer, run by Xiangya Hospital of Central South University, not yet recruiting.","route":"/trials/nct06866977/","status":"planned","kind":"trial","cancerIcon":"locally-advanced-pdac","sub":"NCT06866977","facets":{"kind":["Trial"],"cancers":["Locally advanced unresectable pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06758544","name":"A Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of VRT106 in Combination With Chemotherapy for Resectable Pancreatic Cancer","tldr":"A phase 1/2 trial in pancreatic cancer, run by Guangdong Provincial People's Hospital, now recruiting.","route":"/trials/nct06758544/","status":"recruiting","kind":"trial","cancerIcon":"resectable-pdac","sub":"NCT06758544","facets":{"kind":["Trial"],"cancers":["Resectable pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Resectable pancreatic ductal adenocarcinoma","href":"/cancers/resectable-pdac/","tip":"Resectable pancreatic cancer is the minority of pancreatic cancer that the surgeon can remove with clear margins because it has not wrapped around the main arteries or spread. Treatment is an operation, usually a Whipple procedure, followed by six months of combination chemotherapy, which is what turns surgery alone into a real chance of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05969171","name":"A Single-center, Prospective, Two Cohort Study of Surufatinib Combined With AG or AG in the First-line Treatment of Locally Advanced or Metastatic Pancreatic Ca","tldr":"A phase 2 trial of gemcitabine + nab-paclitaxel in pancreatic cancer, run by Fudan University, now recruiting.","route":"/trials/nct05969171/","status":"recruiting","kind":"trial","cancerIcon":"locally-advanced-pdac","sub":"NCT05969171","facets":{"kind":["Trial"],"cancers":["Locally advanced unresectable pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07138846","name":"A Study Comparing MRG004A Plus Best Supportive Care Versus Placebo and Best Supportive Care in the Treatment of Patients With Advanced Pancreatic Cancer","tldr":"A phase 3 trial in pancreatic cancer, run by Lepu Biopharma Co., Ltd., not yet recruiting.","route":"/trials/nct07138846/","status":"planned","kind":"trial","cancerIcon":"locally-advanced-pdac","sub":"NCT07138846","facets":{"kind":["Trial"],"cancers":["Locally advanced unresectable pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07711067","name":"A Study Comparing Whole-Body Heat Treatment Plus Systemic Therapy to Systemic Therapy Alone, for Advanced Pancreatic Cancer","tldr":"A phase 2/3 trial in pancreatic cancer, run by ElmediX, not yet recruiting.","route":"/trials/nct07711067/","status":"planned","kind":"trial","cancerIcon":"metastatic-pdac","sub":"NCT07711067","facets":{"kind":["Trial"],"cancers":["Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06492941","name":"A Study of Docetaxel for Injection (Albumin Bound) in Patients With Advanced Pancreatic Cancer","tldr":"A phase 3 trial in pancreatic cancer, run by CSPC ZhongQi Pharmaceutical Technology Co., Ltd., not yet recruiting.","route":"/trials/nct06492941/","status":"planned","kind":"trial","cancerIcon":"metastatic-pdac","sub":"NCT06492941","facets":{"kind":["Trial"],"cancers":["Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07383922","name":"A Study of FG-M108+Chemotherapy vs Placebo+Chemotherapy in Claudin18.2-positive Pancreatic Cancer","tldr":"A phase 3 trial of nab-paclitaxel and gemcitabine in pancreatic cancer, run by FutureGen Biopharmaceutical (Beijing) Co., Ltd, not yet recruiting.","route":"/trials/nct07383922/","status":"planned","kind":"trial","cancerIcon":"locally-advanced-pdac","sub":"NCT07383922","facets":{"kind":["Trial"],"cancers":["Locally advanced unresectable pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07678593","name":"A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation","tldr":"A phase 1/2 trial of cetuximab, nab-paclitaxel, gemcitabine, fluorouracil (5-FU) and other drugs in pancreatic cancer, run by Genfleet Therapeutics (Shanghai) Inc., not yet recruiting.","route":"/trials/nct07678593/","status":"planned","kind":"trial","cancerIcon":"metastatic-pdac","sub":"NCT07678593","facets":{"kind":["Trial"],"cancers":["Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07101679","name":"A Study of GnP RegimenCombined With Serplulimab and Stereotactic Body Radiation Therapy as First-line Treatment for Locally Advanced Pancreatic Cancer","tldr":"A phase 2 trial in pancreatic cancer, run by West China Hospital, now recruiting.","route":"/trials/nct07101679/","status":"recruiting","kind":"trial","cancerIcon":"locally-advanced-pdac","sub":"NCT07101679","facets":{"kind":["Trial"],"cancers":["Locally advanced unresectable pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06453486","name":"A Study of High Dose Radiation Therapy for Locally Advanced Pancreatic Cancer That Responded to Initial Chemotherapy Treatment","tldr":"A phase 2 trial in pancreatic cancer, run by University Health Network, Toronto, now recruiting.","route":"/trials/nct06453486/","status":"recruiting","kind":"trial","cancerIcon":"locally-advanced-pdac","sub":"NCT06453486","facets":{"kind":["Trial"],"cancers":["Locally advanced unresectable pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07752875","name":"A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation","tldr":"A phase 1/2 trial in pancreatic cancer, run by LG Chem, not yet recruiting.","route":"/trials/nct07752875/","status":"planned","kind":"trial","cancerIcon":"locally-advanced-pdac","sub":"NCT07752875","facets":{"kind":["Trial"],"cancers":["Locally advanced unresectable pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05624918","name":"A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma","tldr":"A phase 2 trial of nab-paclitaxel, gemcitabine and optune / Optune Pax (TTFields) in pancreatic cancer, run by Ashish Manne, now recruiting.","route":"/trials/nct05624918/","status":"recruiting","kind":"trial","cancerIcon":"resectable-pdac","sub":"NCT05624918","facets":{"kind":["Trial"],"cancers":["Resectable pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Resectable pancreatic ductal adenocarcinoma","href":"/cancers/resectable-pdac/","tip":"Resectable pancreatic cancer is the minority of pancreatic cancer that the surgeon can remove with clear margins because it has not wrapped around the main arteries or spread. Treatment is an operation, usually a Whipple procedure, followed by six months of combination chemotherapy, which is what turns surgery alone into a real chance of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06151262","name":"A Study of Trilaciclib Combined With mFOLFIRINOX in the Treatment of Patients With Advanced Pancreatic Cancer","tldr":"A phase 2 trial in pancreatic cancer, run by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, now recruiting.","route":"/trials/nct06151262/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-pdac","sub":"NCT06151262","facets":{"kind":["Trial"],"cancers":["Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06944106","name":"A Study on Ivonescimab Plus Chemotherapy as Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer","tldr":"A phase 2 trial of ivonescimab in pancreatic cancer, run by Tianjin Medical University Cancer Institute and Hospital, now recruiting.","route":"/trials/nct06944106/","status":"recruiting","kind":"trial","cancerIcon":"borderline-resectable-pdac","sub":"NCT06944106","facets":{"kind":["Trial"],"cancers":["Borderline resectable pancreatic ductal adenocarcinoma","Resectable pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Borderline resectable pancreatic ductal adenocarcinoma","href":"/cancers/borderline-resectable-pdac/","tip":"Borderline resectable pancreatic cancer touches the big blood vessels behind the pancreas, so an operation straight away would probably leave cancer behind. Chemotherapy first, usually FOLFIRINOX for several months and sometimes radiotherapy, shrinks the edge of the tumour, and patients whose disease has not spread go on to surgery with a better chance of a clean removal."},{"label":"Resectable pancreatic ductal adenocarcinoma","href":"/cancers/resectable-pdac/","tip":"Resectable pancreatic cancer is the minority of pancreatic cancer that the surgeon can remove with clear margins because it has not wrapped around the main arteries or spread. Treatment is an operation, usually a Whipple procedure, followed by six months of combination chemotherapy, which is what turns surgery alone into a real chance of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07769502","name":"A Study to Assess Adverse Events and Change in Disease Activity With Treatment Combinations With Telisotuzumab Adizutecan in Adults Participants With Pancreatob","tldr":"A phase 2 trial of telisotuzumab adizutecan, gemcitabine and nab-paclitaxel in pancreatic cancer, run by AbbVie, now recruiting.","route":"/trials/nct07769502/","status":"recruiting","kind":"trial","cancerIcon":"pancreatic","sub":"NCT07769502","facets":{"kind":["Trial"],"cancers":["Pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07803783","name":"A Study to Compare the Efficacy and Safety of YL201 With Standard Chemotherapy in Patients With Metastatic Pancreatic Cancer After Failure of Gemcitabine-Based","tldr":"A phase 3 trial of YL201, liposomal irinotecan, fluorouracil (5-FU) and fLOT (5-FU, leucovorin, oxaliplatin, docetaxel) in pancreatic cancer, run by MediLink Therapeutics (Suzhou) Co., Ltd., not yet recruiting.","route":"/trials/nct07803783/","status":"planned","kind":"trial","cancerIcon":"metastatic-pdac","sub":"NCT07803783","facets":{"kind":["Trial"],"cancers":["Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07272109","name":"Active Anti-diabetic Treatment Plus Chemotherapy for Pancreatic Cancer Related Diabetes","tldr":"A phase 3 trial of nab-paclitaxel and gemcitabine in pancreatic cancer, run by Fudan University, not yet recruiting.","route":"/trials/nct07272109/","status":"planned","kind":"trial","cancerIcon":"metastatic-pdac","sub":"NCT07272109","facets":{"kind":["Trial"],"cancers":["Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06844422","name":"Adapted Guided Stereotactic Body Radiotherapy Combined With Chemotherapy and Enhancement of Novel Drug Ivonescimab for Pancreatic Cancer (ASCEND)","tldr":"A phase 1/2 trial of ivonescimab in pancreatic cancer, run by Shandong Cancer Hospital and Institute, now recruiting.","route":"/trials/nct06844422/","status":"recruiting","kind":"trial","cancerIcon":"pancreatic","sub":"NCT06844422","facets":{"kind":["Trial"],"cancers":["Pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06531278","name":"Adebelimab Combined With Irinotecan Liposomal Injection, Oxaliplatin, Fluorouracil and Calcium Folinate Are Used in the First-line Treatment of Pancreatic Cance","tldr":"A phase 2 trial of adebrelimab, cAPOX (capecitabine, oxaliplatin), fluorouracil (5-FU) and leucovorin (folinic acid) in pancreatic cancer, run by Jiang Long, now recruiting.","route":"/trials/nct06531278/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-pdac","sub":"NCT06531278","facets":{"kind":["Trial"],"cancers":["Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06584227","name":"Adebrelimab and Chidamide for Pancreatic Cancer","tldr":"A phase 2 trial of adebrelimab and gemcitabine in pancreatic cancer, run by Liu Xiufeng, now recruiting.","route":"/trials/nct06584227/","status":"recruiting","kind":"trial","cancerIcon":"locally-advanced-pdac","sub":"NCT06584227","facets":{"kind":["Trial"],"cancers":["Locally advanced unresectable pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06916975","name":"Adebrelimab Combined With AG Regimen in Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer","tldr":"A phase 2 trial of adebrelimab in pancreatic cancer, run by Jin Xu, not yet recruiting.","route":"/trials/nct06916975/","status":"planned","kind":"trial","cancerIcon":"locally-advanced-pdac","sub":"NCT06916975","facets":{"kind":["Trial"],"cancers":["Locally advanced unresectable pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06177522","name":"Adebrelimab Combined With Chemotherapy for Neoadjuvant Therapy in Resectable Pancreatic Cancer","tldr":"A phase 2 trial of adebrelimab, nab-paclitaxel and gemcitabine in pancreatic cancer, run by Jinling Hospital, China, not yet recruiting.","route":"/trials/nct06177522/","status":"planned","kind":"trial","cancerIcon":"resectable-pdac","sub":"NCT06177522","facets":{"kind":["Trial"],"cancers":["Resectable pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Resectable pancreatic ductal adenocarcinoma","href":"/cancers/resectable-pdac/","tip":"Resectable pancreatic cancer is the minority of pancreatic cancer that the surgeon can remove with clear margins because it has not wrapped around the main arteries or spread. Treatment is an operation, usually a Whipple procedure, followed by six months of combination chemotherapy, which is what turns surgery alone into a real chance of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07230301","name":"Adebrelimab Infusion Plus Standard Care for Pancreatic Cancer With Pleural or Peritoneal Effusions","tldr":"A phase 2 trial of adebrelimab in pancreatic cancer, run by Sizhen Wang, not yet recruiting.","route":"/trials/nct07230301/","status":"planned","kind":"trial","cancerIcon":"metastatic-pdac","sub":"NCT07230301","facets":{"kind":["Trial"],"cancers":["Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06427447","name":"Adjuvant Chemoradiotherapy Versus Chemotherapy for Pancreatic Cancer (ADJUPANC)","tldr":"A phase 3 trial in pancreatic cancer, run by Changhai Hospital, now recruiting.","route":"/trials/nct06427447/","status":"recruiting","kind":"trial","cancerIcon":"resectable-pdac","sub":"NCT06427447","facets":{"kind":["Trial"],"cancers":["Resectable pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Resectable pancreatic ductal adenocarcinoma","href":"/cancers/resectable-pdac/","tip":"Resectable pancreatic cancer is the minority of pancreatic cancer that the surgeon can remove with clear margins because it has not wrapped around the main arteries or spread. Treatment is an operation, usually a Whipple procedure, followed by six months of combination chemotherapy, which is what turns surgery alone into a real chance of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct02830724","name":"Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers","tldr":"A phase 1/2 trial of cyclophosphamide, fludarabine and aldesleukin (high-dose IL-2) in pancreatic cancer, run by National Cancer Institute (NCI), now recruiting.","route":"/trials/nct02830724/","status":"recruiting","kind":"trial","cancerIcon":"pancreatic","sub":"NCT02830724","facets":{"kind":["Trial"],"cancers":["Pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03190941","name":"Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients","tldr":"A phase 1/2 trial of cyclophosphamide, fludarabine and aldesleukin (high-dose IL-2) in pancreatic cancer, run by National Cancer Institute (NCI), now recruiting.","route":"/trials/nct03190941/","status":"recruiting","kind":"trial","cancerIcon":"pancreatic","sub":"NCT03190941","facets":{"kind":["Trial"],"cancers":["Pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07208539","name":"AG Followed by FOLFIRINOX Both Combined With PD-L1 Antibodies as a Conversion Therapy for Borderline Resectable and Locally Advanced Pancreatic Cancer.","tldr":"A phase 2 trial in pancreatic cancer, run by Shanghai Zhongshan Hospital, not yet recruiting.","route":"/trials/nct07208539/","status":"planned","kind":"trial","cancerIcon":"borderline-resectable-pdac","sub":"NCT07208539","facets":{"kind":["Trial"],"cancers":["Borderline resectable pancreatic ductal adenocarcinoma","Resectable pancreatic ductal adenocarcinoma","Locally advanced unresectable pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Borderline resectable pancreatic ductal adenocarcinoma","href":"/cancers/borderline-resectable-pdac/","tip":"Borderline resectable pancreatic cancer touches the big blood vessels behind the pancreas, so an operation straight away would probably leave cancer behind. Chemotherapy first, usually FOLFIRINOX for several months and sometimes radiotherapy, shrinks the edge of the tumour, and patients whose disease has not spread go on to surgery with a better chance of a clean removal."},{"label":"Resectable pancreatic ductal adenocarcinoma","href":"/cancers/resectable-pdac/","tip":"Resectable pancreatic cancer is the minority of pancreatic cancer that the surgeon can remove with clear margins because it has not wrapped around the main arteries or spread. Treatment is an operation, usually a Whipple procedure, followed by six months of combination chemotherapy, which is what turns surgery alone into a real chance of cure."},{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06938503","name":"AG Plus Nimotuzumab Sequential Irreversible Electroporation Ablation for Locally Advanced Pancreatic Cancer","tldr":"A phase 2 trial of gemcitabine + nab-paclitaxel and nimotuzumab in pancreatic cancer, run by Tianjin Medical University Cancer Institute and Hospital, not yet recruiting.","route":"/trials/nct06938503/","status":"planned","kind":"trial","cancerIcon":"locally-advanced-pdac","sub":"NCT06938503","facets":{"kind":["Trial"],"cancers":["Locally advanced unresectable pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07831330","name":"Albumin-bound Paclitaxel (II) in Combination With Gemcitabine as First Line Therapy for Metastatic Pancreatic Cancer","tldr":"A phase 2 trial of nab-paclitaxel and gemcitabine in pancreatic cancer, run by The First Affiliated Hospital with Nanjing Medical University, not yet recruiting.","route":"/trials/nct07831330/","status":"planned","kind":"trial","cancerIcon":"metastatic-pdac","sub":"NCT07831330","facets":{"kind":["Trial"],"cancers":["Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07828756","name":"Albumin-bound Paclitaxel (II)-Combined Regimens for Pancreatic Cancer","tldr":"A phase 2 trial of cisplatin, nab-paclitaxel, capecitabine and gemcitabine in pancreatic cancer, run by Tianjin Medical University Cancer Institute and Hospital, not yet recruiting.","route":"/trials/nct07828756/","status":"planned","kind":"trial","cancerIcon":"locally-advanced-pdac","sub":"NCT07828756","facets":{"kind":["Trial"],"cancers":["Locally advanced unresectable pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06789679","name":"Albumin-Bound Paclitaxel and Gemcitabine With or Without S-1 as First-Line Treatment for Advanced Pancreatic Cancer","tldr":"A phase 2 trial in pancreatic cancer, run by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, now recruiting.","route":"/trials/nct06789679/","status":"recruiting","kind":"trial","cancerIcon":"locally-advanced-pdac","sub":"NCT06789679","facets":{"kind":["Trial"],"cancers":["Locally advanced unresectable pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06938282","name":"An Exploratory Clinical Study of HRS-4642 in Combination With Immunotherapy and Chemotherapy for Pancreatic Cancer","tldr":"A phase 2 trial in pancreatic cancer, run by Shanghai Zhongshan Hospital, now recruiting.","route":"/trials/nct06938282/","status":"recruiting","kind":"trial","cancerIcon":"pancreatic","sub":"NCT06938282","facets":{"kind":["Trial"],"cancers":["Pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07631871","name":"An Exploratory Study of Zanidatamab in HER2-positive Advanced Tumor After at Least One Line of Standard Therapy","tldr":"A phase 2 trial of zanidatamab in pancreatic cancer, run by Haihua Yuan, not yet recruiting.","route":"/trials/nct07631871/","status":"planned","kind":"trial","cancerIcon":"metastatic-pdac","sub":"NCT07631871","facets":{"kind":["Trial"],"cancers":["Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07806058","name":"An Open-Label, Multicenter, Phase IB/II Clinical Study of HRS-7172 in Combination With Antitumor Therapy in Participants With Solid Tumors","tldr":"A phase 1/2 trial of adebrelimab in pancreatic cancer, run by Jiangsu HengRui Medicine Co., Ltd., not yet recruiting.","route":"/trials/nct07806058/","status":"planned","kind":"trial","cancerIcon":"locally-advanced-pdac","sub":"NCT07806058","facets":{"kind":["Trial"],"cancers":["Locally advanced unresectable pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06621095","name":"Anlotinib Plus Benmelstobart and AG in First-line Treatment of Advanced Metastatic Pancreatic Cancer (ALTER-PA-001)","tldr":"A phase 2 trial of gemcitabine + nab-paclitaxel in pancreatic cancer, run by RenJi Hospital, not yet recruiting.","route":"/trials/nct06621095/","status":"planned","kind":"trial","cancerIcon":"metastatic-pdac","sub":"NCT06621095","facets":{"kind":["Trial"],"cancers":["Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04858334","name":"APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a","tldr":"A phase 2 trial of olaparib in pancreatic cancer, run by National Cancer Institute (NCI), now recruiting.","route":"/trials/nct04858334/","status":"recruiting","kind":"trial","cancerIcon":"resectable-pdac","sub":"NCT04858334","facets":{"kind":["Trial"],"cancers":["Resectable pancreatic ductal adenocarcinoma","BRCA or PALB2-mutant pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Resectable pancreatic ductal adenocarcinoma","href":"/cancers/resectable-pdac/","tip":"Resectable pancreatic cancer is the minority of pancreatic cancer that the surgeon can remove with clear margins because it has not wrapped around the main arteries or spread. Treatment is an operation, usually a Whipple procedure, followed by six months of combination chemotherapy, which is what turns surgery alone into a real chance of cure."},{"label":"BRCA or PALB2-mutant pancreatic ductal adenocarcinoma","href":"/cancers/brca-palb2-pdac/","tip":"BRCA or PALB2-mutant pancreatic cancer is pancreatic cancer in someone who inherited a faulty copy of a gene that repairs broken DNA. These tumours respond better to platinum chemotherapy, and the POLO trial showed that the PARP inhibitor olaparib, taken after platinum has held the disease, delays its return; that made it the first targeted drug approved for a pancreatic cancer subgroup."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05969860","name":"At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer","tldr":"A phase 2 trial in pancreatic cancer, run by Mayo Clinic, now recruiting.","route":"/trials/nct05969860/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-pdac","sub":"NCT05969860","facets":{"kind":["Trial"],"cancers":["Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07537660","name":"Auricular Point Stimulation Plus Dexamethasone for Nausea and Vomiting Caused by Gemcitabine Plus Paclitaxel","tldr":"A phase 2 trial of dexamethasone in pancreatic cancer, run by Second Affiliated Hospital, Zhejiang University, School of Medicine, now recruiting.","route":"/trials/nct07537660/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-pdac","sub":"NCT07537660","facets":{"kind":["Trial"],"cancers":["Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07716228","name":"Auricular Point Stimulation Plus Dexamethasone Versus Standard Antiemetic Regimen for Nausea and Vomiting Caused by Gemcitabine Combined With Paclitaxel Protein","tldr":"A phase 3 trial of dexamethasone in pancreatic cancer, run by Second Affiliated Hospital, Zhejiang University, School of Medicine, now recruiting.","route":"/trials/nct07716228/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-pdac","sub":"NCT07716228","facets":{"kind":["Trial"],"cancers":["Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07354919","name":"Axelopran for Advanced Cancer in Patients Receiving Opioids","tldr":"A phase 2 trial in pancreatic cancer, run by HealthPartners Institute, now recruiting.","route":"/trials/nct07354919/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-pdac","sub":"NCT07354919","facets":{"kind":["Trial"],"cancers":["Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06483555","name":"Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel","tldr":"A phase 1/2 trial of gemcitabine, nab-paclitaxel, erlotinib, nALIRIFOX (liposomal irinotecan + oxaliplatin + 5-FU/LV) and other drugs in pancreatic cancer, run by UNC Lineberger Comprehensive Cancer Center, now recruiting.","route":"/trials/nct06483555/","status":"recruiting","kind":"trial","cancerIcon":"borderline-resectable-pdac","sub":"NCT06483555","facets":{"kind":["Trial"],"cancers":["Borderline resectable pancreatic ductal adenocarcinoma","Locally advanced unresectable pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Borderline resectable pancreatic ductal adenocarcinoma","href":"/cancers/borderline-resectable-pdac/","tip":"Borderline resectable pancreatic cancer touches the big blood vessels behind the pancreas, so an operation straight away would probably leave cancer behind. Chemotherapy first, usually FOLFIRINOX for several months and sometimes radiotherapy, shrinks the edge of the tumour, and patients whose disease has not spread go on to surgery with a better chance of a clean removal."},{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07629609","name":"BEFAST Study, [68Ga]Ga-FAPI Total Body PET/CT for Better and Faster Imaging in Cancer","tldr":"A phase 2 trial in pancreatic cancer, run by Barbara Malene Fischer, now recruiting.","route":"/trials/nct07629609/","status":"recruiting","kind":"trial","cancerIcon":"pancreatic","sub":"NCT07629609","facets":{"kind":["Trial"],"cancers":["Pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06159478","name":"Binimetinib in Patients With BRAF Fusion-positive Low-grade Glioma or Pancreatic Cancer (Perfume)","tldr":"A phase 2 trial in pancreatic cancer, run by National Cancer Center, Japan, now recruiting.","route":"/trials/nct06159478/","status":"recruiting","kind":"trial","cancerIcon":"pancreatic","sub":"NCT06159478","facets":{"kind":["Trial"],"cancers":["Pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07410494","name":"Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors","tldr":"A phase 1/2 trial in pancreatic cancer, run by Essen Biotech, now recruiting.","route":"/trials/nct07410494/","status":"recruiting","kind":"trial","cancerIcon":"locally-advanced-pdac","sub":"NCT07410494","facets":{"kind":["Trial"],"cancers":["Locally advanced unresectable pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07226856","name":"BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma","tldr":"A phase 2 trial of gemcitabine, nab-paclitaxel and nivolumab in pancreatic cancer, run by Mayo Clinic, now recruiting.","route":"/trials/nct07226856/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-pdac","sub":"NCT07226856","facets":{"kind":["Trial"],"cancers":["Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06572813","name":"Bortezomib Combined with PD-1 MAb and MFOLFIRINOX for Metastatic Pancreatic Cancer","tldr":"A phase 1/2 trial of sintilimab and fOLFIRINOX / mFOLFIRINOX in pancreatic cancer, run by First Affiliated Hospital of Zhejiang University, now recruiting.","route":"/trials/nct06572813/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-pdac","sub":"NCT06572813","facets":{"kind":["Trial"],"cancers":["Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06532617","name":"Cadonilimab Combined With S-1 or Capecitabine as Second-line Treatment for Advanced Pancreatic Cancer","tldr":"A phase 2 trial of cadonilimab in pancreatic cancer, run by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, now recruiting.","route":"/trials/nct06532617/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-pdac","sub":"NCT06532617","facets":{"kind":["Trial"],"cancers":["Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07257523","name":"Carbon Ion Radiotherapy in Frail Patients With Pancreatic Cancer","tldr":"A phase 2 trial in pancreatic cancer, run by Yonsei University, now recruiting.","route":"/trials/nct07257523/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-pdac","sub":"NCT07257523","facets":{"kind":["Trial"],"cancers":["Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07433283","name":"Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor","tldr":"A phase 1/2 trial in pancreatic cancer, run by Sichuan Enray Pharmaceutical Sciences Company, now recruiting.","route":"/trials/nct07433283/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-pdac","sub":"NCT07433283","facets":{"kind":["Trial"],"cancers":["Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07153289","name":"CD318-targeted CAR-T Cell Therapy in Patients With Pancreatic Cancer (ResCPa)","tldr":"A phase 1/2 trial in pancreatic cancer, run by University Hospital Tuebingen, not yet recruiting.","route":"/trials/nct07153289/","status":"planned","kind":"trial","cancerIcon":"pancreatic","sub":"NCT07153289","facets":{"kind":["Trial"],"cancers":["Pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06790602","name":"Cemiplimab Plus Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma","tldr":"A phase 2 trial in pancreatic cancer, run by University of California, San Diego, now recruiting.","route":"/trials/nct06790602/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-pdac","sub":"NCT06790602","facets":{"kind":["Trial"],"cancers":["Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06427460","name":"Central-boost Ablative Radiation Therapy for Solid Tumors (CBART)","tldr":"A phase 2 trial in pancreatic cancer, run by Changhai Hospital, now recruiting.","route":"/trials/nct06427460/","status":"recruiting","kind":"trial","cancerIcon":"pancreatic","sub":"NCT06427460","facets":{"kind":["Trial"],"cancers":["Pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06095141","name":"Cisplatin to Patients With Pancreatic Cancer and Homologous Recombination Deficiency","tldr":"A phase 2/3 trial of cisplatin in pancreatic cancer, run by Fudan University, now recruiting.","route":"/trials/nct06095141/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-pdac","sub":"NCT06095141","facets":{"kind":["Trial"],"cancers":["Metastatic pancreatic ductal adenocarcinoma","BRCA or PALB2-mutant pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."},{"label":"BRCA or PALB2-mutant pancreatic ductal adenocarcinoma","href":"/cancers/brca-palb2-pdac/","tip":"BRCA or PALB2-mutant pancreatic cancer is pancreatic cancer in someone who inherited a faulty copy of a gene that repairs broken DNA. These tumours respond better to platinum chemotherapy, and the POLO trial showed that the PARP inhibitor olaparib, taken after platinum has held the disease, delays its return; that made it the first targeted drug approved for a pancreatic cancer subgroup."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06199895","name":"Clinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Patients With Taxans-resistant Pancreatic Adenocarcinoma, Cholan","tldr":"A phase 2 trial in pancreatic cancer, run by Liu Huang, now recruiting.","route":"/trials/nct06199895/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-pdac","sub":"NCT06199895","facets":{"kind":["Trial"],"cancers":["Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03093688","name":"Clinical Safty and Efficacy Study of Infusion of iNKT Cells and CD8+T Cells in Patients With Advanced Solid Tumor","tldr":"A phase 1/2 trial in pancreatic cancer, run by Shanghai Public Health Clinical Center, now recruiting.","route":"/trials/nct03093688/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-pdac","sub":"NCT03093688","facets":{"kind":["Trial"],"cancers":["Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07827053","name":"Clinical Study of Radiotherapy Combined With Adebrelimab and NALIRIFOX for Conversion Therapy in Locally Advanced Pancreatic Cancer","tldr":"A phase 2 trial of adebrelimab and nALIRIFOX (liposomal irinotecan + oxaliplatin + 5-FU/LV) in pancreatic cancer, run by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, not yet recruiting.","route":"/trials/nct07827053/","status":"planned","kind":"trial","cancerIcon":"locally-advanced-pdac","sub":"NCT07827053","facets":{"kind":["Trial"],"cancers":["Locally advanced unresectable pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06233877","name":"Clinical Trial Evaluating Low Dose G-FLIP Plus Mitomycin C for Stage IV Pancreatic Cancer","tldr":"A phase 2 trial of mitomycin C in pancreatic cancer, run by Hirschfeld Oncology, not yet recruiting.","route":"/trials/nct06233877/","status":"planned","kind":"trial","cancerIcon":"metastatic-pdac","sub":"NCT06233877","facets":{"kind":["Trial"],"cancers":["Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06255912","name":"Clinical Trial for Advanced or Metastatic Pancreatic Cancer","tldr":"A phase 2 trial in pancreatic cancer, run by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, not yet recruiting.","route":"/trials/nct06255912/","status":"planned","kind":"trial","cancerIcon":"locally-advanced-pdac","sub":"NCT06255912","facets":{"kind":["Trial"],"cancers":["Locally advanced unresectable pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07656376","name":"Clinical Trial of DN022150 Combined With AG Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12D Mutation","tldr":"A phase 2/3 trial in pancreatic cancer, run by Jiangxi Kvvit Pharmaceutical Co., Ltd., not yet recruiting.","route":"/trials/nct07656376/","status":"planned","kind":"trial","cancerIcon":"locally-advanced-pdac","sub":"NCT07656376","facets":{"kind":["Trial"],"cancers":["Locally advanced unresectable pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05927142","name":"Combining Anti-PD-L1 Immune Checkpoint Inhibitor Durvalumab With TLR-3 Agonist Rintatolimod in Patients With Metastatic Pancreatic Ductal Adenocarcinoma for The","tldr":"A phase 1/2 trial of durvalumab in pancreatic cancer, run by Joachim Aerts, MD PhD, now recruiting.","route":"/trials/nct05927142/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-pdac","sub":"NCT05927142","facets":{"kind":["Trial"],"cancers":["Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06234072","name":"Comparing Astragalus Plus Gemcitabine to Gemcitabine Alone as Neoadjuvant Treatment for Pancreatic Cancer Patients","tldr":"A phase 2 trial of gemcitabine in pancreatic cancer, run by Shenzhen University General Hospital, not yet recruiting.","route":"/trials/nct06234072/","status":"planned","kind":"trial","cancerIcon":"resectable-pdac","sub":"NCT06234072","facets":{"kind":["Trial"],"cancers":["Resectable pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Resectable pancreatic ductal adenocarcinoma","href":"/cancers/resectable-pdac/","tip":"Resectable pancreatic cancer is the minority of pancreatic cancer that the surgeon can remove with clear margins because it has not wrapped around the main arteries or spread. Treatment is an operation, usually a Whipple procedure, followed by six months of combination chemotherapy, which is what turns surgery alone into a real chance of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06782932","name":"Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer","tldr":"A phase 1/2 trial of balstilimab and cyclophosphamide in pancreatic cancer, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, now recruiting.","route":"/trials/nct06782932/","status":"recruiting","kind":"trial","cancerIcon":"resectable-pdac","sub":"NCT06782932","facets":{"kind":["Trial"],"cancers":["Resectable pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Resectable pancreatic ductal adenocarcinoma","href":"/cancers/resectable-pdac/","tip":"Resectable pancreatic cancer is the minority of pancreatic cancer that the surgeon can remove with clear margins because it has not wrapped around the main arteries or spread. Treatment is an operation, usually a Whipple procedure, followed by six months of combination chemotherapy, which is what turns surgery alone into a real chance of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06690528","name":"Conversion Surgery Vs. Palliative Care in Pancreatic Cancer Oligometastatic to the Liver","tldr":"A phase 2 trial in pancreatic cancer, run by Azienda Ospedaliera di Padova, now recruiting.","route":"/trials/nct06690528/","status":"recruiting","kind":"trial","cancerIcon":"borderline-resectable-pdac","sub":"NCT06690528","facets":{"kind":["Trial"],"cancers":["Borderline resectable pancreatic ductal adenocarcinoma","Resectable pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Borderline resectable pancreatic ductal adenocarcinoma","href":"/cancers/borderline-resectable-pdac/","tip":"Borderline resectable pancreatic cancer touches the big blood vessels behind the pancreas, so an operation straight away would probably leave cancer behind. Chemotherapy first, usually FOLFIRINOX for several months and sometimes radiotherapy, shrinks the edge of the tumour, and patients whose disease has not spread go on to surgery with a better chance of a clean removal."},{"label":"Resectable pancreatic ductal adenocarcinoma","href":"/cancers/resectable-pdac/","tip":"Resectable pancreatic cancer is the minority of pancreatic cancer that the surgeon can remove with clear margins because it has not wrapped around the main arteries or spread. Treatment is an operation, usually a Whipple procedure, followed by six months of combination chemotherapy, which is what turns surgery alone into a real chance of cure."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07306286","name":"Cryoablation Combined With the Dual-Function Antibody PD-1/CTLA-4 for the Treatment of LAPC Following Failure of First-Line AG Therapy","tldr":"A phase 2 trial in pancreatic cancer, run by Ruijin Hospital, now recruiting.","route":"/trials/nct07306286/","status":"recruiting","kind":"trial","cancerIcon":"locally-advanced-pdac","sub":"NCT07306286","facets":{"kind":["Trial"],"cancers":["Locally advanced unresectable pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07595835","name":"CT-guided Percutaneous Radionuclide Therapy With 32P Microparticles in Patients With Non-progressive Locally Advanced Pancreatic Cancer","tldr":"A phase 1/2 trial in pancreatic cancer, run by M.R. Meijerink, now recruiting.","route":"/trials/nct07595835/","status":"recruiting","kind":"trial","cancerIcon":"locally-advanced-pdac","sub":"NCT07595835","facets":{"kind":["Trial"],"cancers":["Locally advanced unresectable pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06659705","name":"Cutting Edge Imaging With PET-FAPI for Earlier Pancreatic Cancer Diagnosis (INDIGO-FAPI)","tldr":"A phase 2 trial in pancreatic cancer, run by Institut Curie, now recruiting.","route":"/trials/nct06659705/","status":"recruiting","kind":"trial","cancerIcon":"pancreatic","sub":"NCT06659705","facets":{"kind":["Trial"],"cancers":["Pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07705919","name":"DCE-MRI for Neoadjuvant Treatment Assessment in Patients With Borderline Resectable Pancreatic Cancer","tldr":"A phase 1/2 trial of fluorouracil (5-FU), gemcitabine, fOLFIRI (5-FU, leucovorin, irinotecan), leucovorin (folinic acid) and other drugs in pancreatic cancer, run by Ohio State University Comprehensive Cancer Center, not yet recruiting.","route":"/trials/nct07705919/","status":"planned","kind":"trial","cancerIcon":"borderline-resectable-pdac","sub":"NCT07705919","facets":{"kind":["Trial"],"cancers":["Borderline resectable pancreatic ductal adenocarcinoma","Resectable pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Borderline resectable pancreatic ductal adenocarcinoma","href":"/cancers/borderline-resectable-pdac/","tip":"Borderline resectable pancreatic cancer touches the big blood vessels behind the pancreas, so an operation straight away would probably leave cancer behind. Chemotherapy first, usually FOLFIRINOX for several months and sometimes radiotherapy, shrinks the edge of the tumour, and patients whose disease has not spread go on to surgery with a better chance of a clean removal."},{"label":"Resectable pancreatic ductal adenocarcinoma","href":"/cancers/resectable-pdac/","tip":"Resectable pancreatic cancer is the minority of pancreatic cancer that the surgeon can remove with clear margins because it has not wrapped around the main arteries or spread. Treatment is an operation, usually a Whipple procedure, followed by six months of combination chemotherapy, which is what turns surgery alone into a real chance of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07440290","name":"DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positi","tldr":"A phase 2/3 trial of dabrafenib and trametinib in pancreatic cancer, run by Cancer Research UK, now recruiting.","route":"/trials/nct07440290/","status":"recruiting","kind":"trial","cancerIcon":"pancreatic","sub":"NCT07440290","facets":{"kind":["Trial"],"cancers":["Pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06333314","name":"Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI","tldr":"A phase 2 trial of dostarlimab in pancreatic cancer, run by UNICANCER, now recruiting.","route":"/trials/nct06333314/","status":"recruiting","kind":"trial","cancerIcon":"locally-advanced-pdac","sub":"NCT06333314","facets":{"kind":["Trial"],"cancers":["Locally advanced unresectable pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma","Mismatch repair deficient (MSI-high) pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."},{"label":"Mismatch repair deficient (MSI-high) pancreatic ductal adenocarcinoma","href":"/cancers/msi-high-pdac/","tip":"Mismatch repair deficient pancreatic cancer is the rare pancreatic cancer whose cells cannot fix spelling errors in DNA and so carry thousands of mutations. That makes it one of the few pancreatic cancers that immunotherapy works against, and pembrolizumab is approved for it, though fewer of these tumours respond than in bowel cancer; testing every pancreatic cancer for the defect is the point."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06757244","name":"DOVIPA, a Study Evaluating Efficacy and Safety of DOstarlimab and VItamin D3 With mFOLFIRINOX in PAncreatic Cancer","tldr":"A phase 2 trial of dostarlimab in pancreatic cancer, run by Hopital Foch, now recruiting.","route":"/trials/nct06757244/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-pdac","sub":"NCT06757244","facets":{"kind":["Trial"],"cancers":["Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07410676","name":"EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors","tldr":"A phase 1/2 trial of pembrolizumab in pancreatic cancer, run by Essen Biotech, now recruiting.","route":"/trials/nct07410676/","status":"recruiting","kind":"trial","cancerIcon":"locally-advanced-pdac","sub":"NCT07410676","facets":{"kind":["Trial"],"cancers":["Locally advanced unresectable pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07108504","name":"Efficacy and Safety of LM-302 Combined With Gemcitabine CLDN 18.2 Positive Unresectable Locally Advanced or Metastatic Pancreatic Cancer","tldr":"A phase 2 trial of gemcitabine and LM-302 in pancreatic cancer, run by Shanghai Zhongshan Hospital, not yet recruiting.","route":"/trials/nct07108504/","status":"planned","kind":"trial","cancerIcon":"locally-advanced-pdac","sub":"NCT07108504","facets":{"kind":["Trial"],"cancers":["Locally advanced unresectable pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05116072","name":"Efficacy and Safety of TPIAT for Resectable Adenocarcinoma of the Pancreas Region at High Risk of Postoperative Fistula","tldr":"A phase 1/2 trial in pancreatic cancer, run by University Hospital, Lille, now recruiting.","route":"/trials/nct05116072/","status":"recruiting","kind":"trial","cancerIcon":"resectable-pdac","sub":"NCT05116072","facets":{"kind":["Trial"],"cancers":["Resectable pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Resectable pancreatic ductal adenocarcinoma","href":"/cancers/resectable-pdac/","tip":"Resectable pancreatic cancer is the minority of pancreatic cancer that the surgeon can remove with clear margins because it has not wrapped around the main arteries or spread. Treatment is an operation, usually a Whipple procedure, followed by six months of combination chemotherapy, which is what turns surgery alone into a real chance of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05065801","name":"Efficacy of Gembrax Followed by Folfirinox Versus Folfirinox Alone in First Metastatic Line Pancreatic Cancer Patients","tldr":"A phase 2 trial in pancreatic cancer, run by Institut du Cancer de Montpellier - Val d'Aurelle, now recruiting.","route":"/trials/nct05065801/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-pdac","sub":"NCT05065801","facets":{"kind":["Trial"],"cancers":["Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07600268","name":"Efficacy of Stereotactic Body Radiotherapy (SBRT) Combined With Maintenance Therapy Compared to Maintenance Therapy Alone in Advanced Pancreatic Cancer","tldr":"A phase 2 trial in pancreatic cancer, run by Shandong Cancer Hospital and Institute, now recruiting.","route":"/trials/nct07600268/","status":"recruiting","kind":"trial","cancerIcon":"locally-advanced-pdac","sub":"NCT07600268","facets":{"kind":["Trial"],"cancers":["Locally advanced unresectable pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07446270","name":"Efficacy of Tunlametinib in Combination With Anti-EGFR Monoclonal Antibody in Patients With RAS-Mutated Advanced Gastrointestinal Malignancies","tldr":"A phase 2 trial of cetuximab and nimotuzumab in pancreatic cancer, run by Chinese PLA General Hospital, not yet recruiting.","route":"/trials/nct07446270/","status":"planned","kind":"trial","cancerIcon":"metastatic-pdac","sub":"NCT07446270","facets":{"kind":["Trial"],"cancers":["Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07698613","name":"EGFR Targeted Photoimmunotherapy With ASP-1929 for Locally Advanced Pancreatic Cancer","tldr":"A phase 1/2 trial in pancreatic cancer, run by Brown University, not yet recruiting.","route":"/trials/nct07698613/","status":"planned","kind":"trial","cancerIcon":"borderline-resectable-pdac","sub":"NCT07698613","facets":{"kind":["Trial"],"cancers":["Borderline resectable pancreatic ductal adenocarcinoma","Resectable pancreatic ductal adenocarcinoma","Locally advanced unresectable pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Borderline resectable pancreatic ductal adenocarcinoma","href":"/cancers/borderline-resectable-pdac/","tip":"Borderline resectable pancreatic cancer touches the big blood vessels behind the pancreas, so an operation straight away would probably leave cancer behind. Chemotherapy first, usually FOLFIRINOX for several months and sometimes radiotherapy, shrinks the edge of the tumour, and patients whose disease has not spread go on to surgery with a better chance of a clean removal."},{"label":"Resectable pancreatic ductal adenocarcinoma","href":"/cancers/resectable-pdac/","tip":"Resectable pancreatic cancer is the minority of pancreatic cancer that the surgeon can remove with clear margins because it has not wrapped around the main arteries or spread. Treatment is an operation, usually a Whipple procedure, followed by six months of combination chemotherapy, which is what turns surgery alone into a real chance of cure."},{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06831136","name":"Endoscopic Ultrasound Radiofrequency Ablation and Immunotherapy Pembrolizumab for Locally Advanced Unresectable and Metastatic Pancreatic Duct Adenocarcinoma","tldr":"A phase 2 trial in pancreatic cancer, run by The University of Texas Health Science Center, Houston, now recruiting.","route":"/trials/nct06831136/","status":"recruiting","kind":"trial","cancerIcon":"locally-advanced-pdac","sub":"NCT06831136","facets":{"kind":["Trial"],"cancers":["Locally advanced unresectable pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07429643","name":"Endoscopic Ultrasound-Guided Loco-regional Chemotherapy Injection as Adjuvant Therapy for Locally Advanced Pancreatic Cancer.","tldr":"A phase 2/3 trial in pancreatic cancer, run by Assiut University, not yet recruiting.","route":"/trials/nct07429643/","status":"planned","kind":"trial","cancerIcon":"resectable-pdac","sub":"NCT07429643","facets":{"kind":["Trial"],"cancers":["Resectable pancreatic ductal adenocarcinoma","Locally advanced unresectable pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Resectable pancreatic ductal adenocarcinoma","href":"/cancers/resectable-pdac/","tip":"Resectable pancreatic cancer is the minority of pancreatic cancer that the surgeon can remove with clear margins because it has not wrapped around the main arteries or spread. Treatment is an operation, usually a Whipple procedure, followed by six months of combination chemotherapy, which is what turns surgery alone into a real chance of cure."},{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04990609","name":"EUS-RFA PANCARDINAL-1 Trial","tldr":"A phase 2 trial in pancreatic cancer, run by The University of Texas Health Science Center, Houston, now recruiting.","route":"/trials/nct04990609/","status":"recruiting","kind":"trial","cancerIcon":"pancreatic","sub":"NCT04990609","facets":{"kind":["Trial"],"cancers":["Pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04485286","name":"Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury","tldr":"A phase 2 trial in pancreatic cancer, run by Massachusetts General Hospital, now recruiting.","route":"/trials/nct04485286/","status":"recruiting","kind":"trial","cancerIcon":"pancreatic","sub":"NCT04485286","facets":{"kind":["Trial"],"cancers":["Pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07097064","name":"Evaluation of the Stereotactic MR-guided Adaptive Radiotherapy for Locally Advanced Pancreatic Cancers","tldr":"A phase 2 trial in pancreatic cancer, run by Institut du Cancer de Montpellier - Val d'Aurelle, not yet recruiting.","route":"/trials/nct07097064/","status":"planned","kind":"trial","cancerIcon":"locally-advanced-pdac","sub":"NCT07097064","facets":{"kind":["Trial"],"cancers":["Locally advanced unresectable pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07670312","name":"Evaluation of XYA02 in Patients With Advanced Solid Tumors","tldr":"A phase 1/2 trial in pancreatic cancer, run by XYone Therapeutics, Inc, not yet recruiting.","route":"/trials/nct07670312/","status":"planned","kind":"trial","cancerIcon":"metastatic-pdac","sub":"NCT07670312","facets":{"kind":["Trial"],"cancers":["Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06145074","name":"Examining Safety, Efficacy and Feasibility of Preoperative Propranolol in Patients With PDAC.","tldr":"A phase 2 trial of propranolol (Hemangeol) in pancreatic cancer, run by Zealand University Hospital, now recruiting.","route":"/trials/nct06145074/","status":"recruiting","kind":"trial","cancerIcon":"resectable-pdac","sub":"NCT06145074","facets":{"kind":["Trial"],"cancers":["Resectable pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Resectable pancreatic ductal adenocarcinoma","href":"/cancers/resectable-pdac/","tip":"Resectable pancreatic cancer is the minority of pancreatic cancer that the surgeon can remove with clear margins because it has not wrapped around the main arteries or spread. Treatment is an operation, usually a Whipple procedure, followed by six months of combination chemotherapy, which is what turns surgery alone into a real chance of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06427239","name":"Exploratory Clinical Study of HRS-4642 Combined With Adebrelimab in the Treatment of Advanced Pancreatic Ductal Adenocarcinoma","tldr":"A phase 1/2 trial of adebrelimab and SHR-8068 in pancreatic cancer, run by Fudan University, now recruiting.","route":"/trials/nct06427239/","status":"recruiting","kind":"trial","cancerIcon":"locally-advanced-pdac","sub":"NCT06427239","facets":{"kind":["Trial"],"cancers":["Locally advanced unresectable pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06547736","name":"Exploratory Platform Research on Precision Therapy of Advanced Pancreatic Cancer","tldr":"A phase 2 trial of adebrelimab in pancreatic cancer, run by Fudan University, now recruiting.","route":"/trials/nct06547736/","status":"recruiting","kind":"trial","cancerIcon":"locally-advanced-pdac","sub":"NCT06547736","facets":{"kind":["Trial"],"cancers":["Locally advanced unresectable pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06593431","name":"Extending Outcomes for Pancreas Cancer Patients With Nominal Oligometastatic Disease (EXPAND): A Randomized Phase III Trial","tldr":"A phase 3 trial in pancreatic cancer, run by M.D. Anderson Cancer Center, now recruiting.","route":"/trials/nct06593431/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-pdac","sub":"NCT06593431","facets":{"kind":["Trial"],"cancers":["Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07705074","name":"FAPI PET Imaging - An Exploratory Study","tldr":"A phase 1/2 trial in pancreatic cancer, run by Martin Huellner, not yet recruiting.","route":"/trials/nct07705074/","status":"planned","kind":"trial","cancerIcon":"metastatic-pdac","sub":"NCT07705074","facets":{"kind":["Trial"],"cancers":["Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07235930","name":"Firstline Sequential AG and mFOLFOX Combined With Serplulimab and Bevacizumab Versus AG Chemotherapy Alone in Advanced Pancreatic Cancer","tldr":"A phase 3 trial of bevacizumab and gemcitabine + nab-paclitaxel in pancreatic cancer, run by Zhejiang Cancer Hospital, now recruiting.","route":"/trials/nct07235930/","status":"recruiting","kind":"trial","cancerIcon":"locally-advanced-pdac","sub":"NCT07235930","facets":{"kind":["Trial"],"cancers":["Locally advanced unresectable pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05438459","name":"GAIA-102 Intraperitoneal Administration in Patients With Advanced Gastrointestinal Cancer of Microsatellite Stable With Malignant Ascites","tldr":"A phase 1/2 trial of pembrolizumab, trifluridine/tipiracil and fluorouracil (5-FU) in pancreatic cancer, run by Kyushu University, now recruiting.","route":"/trials/nct05438459/","status":"recruiting","kind":"trial","cancerIcon":"locally-advanced-pdac","sub":"NCT05438459","facets":{"kind":["Trial"],"cancers":["Locally advanced unresectable pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03498326","name":"Gemcitabine and Celecoxib Combination Therapy in Treating Patients With R0 Resection Pancreatic Cancer","tldr":"A phase 2 trial of gemcitabine in pancreatic cancer, run by Second Affiliated Hospital, Zhejiang University, School of Medicine, now recruiting.","route":"/trials/nct03498326/","status":"recruiting","kind":"trial","cancerIcon":"pancreatic","sub":"NCT03498326","facets":{"kind":["Trial"],"cancers":["Pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06897644","name":"Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuation of Modified FOLFIRINOX as 1st Line Chemotherapy in Patients With Advanced Pancreatic C","tldr":"A phase 3 trial of cAPOX (capecitabine, oxaliplatin), fOLFIRI (5-FU, leucovorin, irinotecan), fLOT (5-FU, leucovorin, oxaliplatin, docetaxel), fluorouracil (5-FU) and other drugs in pancreatic cancer, run by Gruppo Oncologico del Nord-Ovest, now recruiting.","route":"/trials/nct06897644/","status":"recruiting","kind":"trial","cancerIcon":"locally-advanced-pdac","sub":"NCT06897644","facets":{"kind":["Trial"],"cancers":["Locally advanced unresectable pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05841420","name":"Gemcitabine Versus Reduced-dose Combination Chemotherapy in Fragile Patients with Non-resectable Pancreatic Cancer","tldr":"A phase 2 trial of gemcitabine and nab-paclitaxel in pancreatic cancer, run by Morten Ladekarl, now recruiting.","route":"/trials/nct05841420/","status":"recruiting","kind":"trial","cancerIcon":"locally-advanced-pdac","sub":"NCT05841420","facets":{"kind":["Trial"],"cancers":["Locally advanced unresectable pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06423326","name":"Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer","tldr":"A phase 2 trial of cisplatin, gemcitabine and nab-paclitaxel in pancreatic cancer, run by Emory University, now recruiting.","route":"/trials/nct06423326/","status":"recruiting","kind":"trial","cancerIcon":"borderline-resectable-pdac","sub":"NCT06423326","facets":{"kind":["Trial"],"cancers":["Borderline resectable pancreatic ductal adenocarcinoma","Resectable pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Borderline resectable pancreatic ductal adenocarcinoma","href":"/cancers/borderline-resectable-pdac/","tip":"Borderline resectable pancreatic cancer touches the big blood vessels behind the pancreas, so an operation straight away would probably leave cancer behind. Chemotherapy first, usually FOLFIRINOX for several months and sometimes radiotherapy, shrinks the edge of the tumour, and patients whose disease has not spread go on to surgery with a better chance of a clean removal."},{"label":"Resectable pancreatic ductal adenocarcinoma","href":"/cancers/resectable-pdac/","tip":"Resectable pancreatic cancer is the minority of pancreatic cancer that the surgeon can remove with clear margins because it has not wrapped around the main arteries or spread. Treatment is an operation, usually a Whipple procedure, followed by six months of combination chemotherapy, which is what turns surgery alone into a real chance of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06576115","name":"Gemcitabine, Nab-paclitaxel Plus the TheraBionic P1 (an Amplitude-Modulated Radiofrequency Electromagnetic Fields) Device to Treat Metastatic Pancreatic Cancer","tldr":"A phase 2 trial of nab-paclitaxel and gemcitabine in pancreatic cancer, run by Barbara Ann Karmanos Cancer Institute, now recruiting.","route":"/trials/nct06576115/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-pdac","sub":"NCT06576115","facets":{"kind":["Trial"],"cancers":["Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07802184","name":"GnP Combined With SHR-1701 and Apatinib as First-Line Treatment for Locally Advanced or Metastatic PDAC","tldr":"A phase 1/2 trial of retlirafusp alfa, rivoceranib (apatinib), gemcitabine and nab-paclitaxel in pancreatic cancer, run by West China Hospital, not yet recruiting.","route":"/trials/nct07802184/","status":"planned","kind":"trial","cancerIcon":"locally-advanced-pdac","sub":"NCT07802184","facets":{"kind":["Trial"],"cancers":["Locally advanced unresectable pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07504471","name":"Hepatic Arterial Infusion of Sodium Bicarbonate (NaHCO3) Combined With NASOX Regimen and Programmed Death-1 (PD-1) Inhibitors for Pancreatic Cancer Liver Metast","tldr":"A phase 2 trial in pancreatic cancer, run by Ruijin Hospital, now recruiting.","route":"/trials/nct07504471/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-pdac","sub":"NCT07504471","facets":{"kind":["Trial"],"cancers":["Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05810792","name":"Histamine Dihydrochloride and Interleukin-2 in Primary Resectable Pancreatic Cancer","tldr":"A phase 2 trial of histamine dihydrochloride and aldesleukin (high-dose IL-2) in pancreatic cancer, run by Sahlgrenska University Hospital, not yet recruiting.","route":"/trials/nct05810792/","status":"planned","kind":"trial","cancerIcon":"resectable-pdac","sub":"NCT05810792","facets":{"kind":["Trial"],"cancers":["Resectable pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Resectable pancreatic ductal adenocarcinoma","href":"/cancers/resectable-pdac/","tip":"Resectable pancreatic cancer is the minority of pancreatic cancer that the surgeon can remove with clear margins because it has not wrapped around the main arteries or spread. Treatment is an operation, usually a Whipple procedure, followed by six months of combination chemotherapy, which is what turns surgery alone into a real chance of cure."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06217042","name":"HR070803 in Combination With Oxaliplatin, 5-fluorouracil/LV Versus GX as Adjuvant Therapy for Pancreatic Cancer","tldr":"A phase 3 trial of liposomal irinotecan, cAPOX (capecitabine, oxaliplatin), leucovorin (folinic acid), gemcitabine and other drugs in pancreatic cancer, run by Fudan University, not yet recruiting.","route":"/trials/nct06217042/","status":"planned","kind":"trial","cancerIcon":"resectable-pdac","sub":"NCT06217042","facets":{"kind":["Trial"],"cancers":["Resectable pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Resectable pancreatic ductal adenocarcinoma","href":"/cancers/resectable-pdac/","tip":"Resectable pancreatic cancer is the minority of pancreatic cancer that the surgeon can remove with clear margins because it has not wrapped around the main arteries or spread. Treatment is an operation, usually a Whipple procedure, followed by six months of combination chemotherapy, which is what turns surgery alone into a real chance of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06383078","name":"HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer","tldr":"A phase 2 trial of liposomal irinotecan, cAPOX (capecitabine, oxaliplatin), tegafur, gimeracil and oteracil (S-1), leucovorin (folinic acid) and other drugs in pancreatic cancer, run by The First Affiliated Hospital with Nanjing Medical University, not yet recruiting.","route":"/trials/nct06383078/","status":"planned","kind":"trial","cancerIcon":"resectable-pdac","sub":"NCT06383078","facets":{"kind":["Trial"],"cancers":["Resectable pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Resectable pancreatic ductal adenocarcinoma","href":"/cancers/resectable-pdac/","tip":"Resectable pancreatic cancer is the minority of pancreatic cancer that the surgeon can remove with clear margins because it has not wrapped around the main arteries or spread. Treatment is an operation, usually a Whipple procedure, followed by six months of combination chemotherapy, which is what turns surgery alone into a real chance of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06587061","name":"HRS-4642 in Combination With AG for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer","tldr":"A phase 2 trial in pancreatic cancer, run by Ruijin Hospital, now recruiting.","route":"/trials/nct06587061/","status":"recruiting","kind":"trial","cancerIcon":"resectable-pdac","sub":"NCT06587061","facets":{"kind":["Trial"],"cancers":["Resectable pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Resectable pancreatic ductal adenocarcinoma","href":"/cancers/resectable-pdac/","tip":"Resectable pancreatic cancer is the minority of pancreatic cancer that the surgeon can remove with clear margins because it has not wrapped around the main arteries or spread. Treatment is an operation, usually a Whipple procedure, followed by six months of combination chemotherapy, which is what turns surgery alone into a real chance of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07131514","name":"HRS-4642 in Combination With Gemcitabine and Albumin-bound Paclitaxel and Adebrelimab for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer","tldr":"A phase 2 trial of adebrelimab in pancreatic cancer, run by Ruijin Hospital, now recruiting.","route":"/trials/nct07131514/","status":"recruiting","kind":"trial","cancerIcon":"resectable-pdac","sub":"NCT07131514","facets":{"kind":["Trial"],"cancers":["Resectable pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Resectable pancreatic ductal adenocarcinoma","href":"/cancers/resectable-pdac/","tip":"Resectable pancreatic cancer is the minority of pancreatic cancer that the surgeon can remove with clear margins because it has not wrapped around the main arteries or spread. Treatment is an operation, usually a Whipple procedure, followed by six months of combination chemotherapy, which is what turns surgery alone into a real chance of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07240766","name":"HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation","tldr":"A phase 2 trial of nimotuzumab in pancreatic cancer, run by Zhejiang University, now recruiting.","route":"/trials/nct07240766/","status":"recruiting","kind":"trial","cancerIcon":"borderline-resectable-pdac","sub":"NCT07240766","facets":{"kind":["Trial"],"cancers":["Borderline resectable pancreatic ductal adenocarcinoma","Resectable pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Borderline resectable pancreatic ductal adenocarcinoma","href":"/cancers/borderline-resectable-pdac/","tip":"Borderline resectable pancreatic cancer touches the big blood vessels behind the pancreas, so an operation straight away would probably leave cancer behind. Chemotherapy first, usually FOLFIRINOX for several months and sometimes radiotherapy, shrinks the edge of the tumour, and patients whose disease has not spread go on to surgery with a better chance of a clean removal."},{"label":"Resectable pancreatic ductal adenocarcinoma","href":"/cancers/resectable-pdac/","tip":"Resectable pancreatic cancer is the minority of pancreatic cancer that the surgeon can remove with clear margins because it has not wrapped around the main arteries or spread. Treatment is an operation, usually a Whipple procedure, followed by six months of combination chemotherapy, which is what turns surgery alone into a real chance of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06770452","name":"HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients","tldr":"A phase 2 trial of nimotuzumab and gemcitabine + nab-paclitaxel in pancreatic cancer, run by Zhejiang University, now recruiting.","route":"/trials/nct06770452/","status":"recruiting","kind":"trial","cancerIcon":"locally-advanced-pdac","sub":"NCT06770452","facets":{"kind":["Trial"],"cancers":["Locally advanced unresectable pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05944237","name":"HTL0039732 in Participants With Advanced Solid Tumours","tldr":"A phase 1/2 trial in pancreatic cancer, run by Cancer Research UK, now recruiting.","route":"/trials/nct05944237/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-pdac","sub":"NCT05944237","facets":{"kind":["Trial"],"cancers":["Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04858009","name":"Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Pancreatic Cancer and Peritoneal Metastasis","tldr":"A phase 2 trial of cisplatin and nab-paclitaxel in pancreatic cancer, run by Mayo Clinic, now recruiting.","route":"/trials/nct04858009/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-pdac","sub":"NCT04858009","facets":{"kind":["Trial"],"cancers":["Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06435260","name":"Hypofractionated Radiotherapy +Chemotherapy+ Camrelizumab as Neoadjuvant Therapy for Pancreatic Cancer","tldr":"A phase 2 trial of camrelizumab in pancreatic cancer, run by Hebei Medical University Fourth Hospital, now recruiting.","route":"/trials/nct06435260/","status":"recruiting","kind":"trial","cancerIcon":"borderline-resectable-pdac","sub":"NCT06435260","facets":{"kind":["Trial"],"cancers":["Borderline resectable pancreatic ductal adenocarcinoma","Resectable pancreatic ductal adenocarcinoma","Locally advanced unresectable pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Borderline resectable pancreatic ductal adenocarcinoma","href":"/cancers/borderline-resectable-pdac/","tip":"Borderline resectable pancreatic cancer touches the big blood vessels behind the pancreas, so an operation straight away would probably leave cancer behind. Chemotherapy first, usually FOLFIRINOX for several months and sometimes radiotherapy, shrinks the edge of the tumour, and patients whose disease has not spread go on to surgery with a better chance of a clean removal."},{"label":"Resectable pancreatic ductal adenocarcinoma","href":"/cancers/resectable-pdac/","tip":"Resectable pancreatic cancer is the minority of pancreatic cancer that the surgeon can remove with clear margins because it has not wrapped around the main arteries or spread. Treatment is an operation, usually a Whipple procedure, followed by six months of combination chemotherapy, which is what turns surgery alone into a real chance of cure."},{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07415525","name":"IBI343 Combined With Chemotherapy as Neoadjuvant Therapy in Borderline Resectable Pancreatic Cancer","tldr":"A phase 2 trial of IBI343 in pancreatic cancer, run by Zhejiang University, not yet recruiting.","route":"/trials/nct07415525/","status":"planned","kind":"trial","cancerIcon":"borderline-resectable-pdac","sub":"NCT07415525","facets":{"kind":["Trial"],"cancers":["Borderline resectable pancreatic ductal adenocarcinoma","Resectable pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Borderline resectable pancreatic ductal adenocarcinoma","href":"/cancers/borderline-resectable-pdac/","tip":"Borderline resectable pancreatic cancer touches the big blood vessels behind the pancreas, so an operation straight away would probably leave cancer behind. Chemotherapy first, usually FOLFIRINOX for several months and sometimes radiotherapy, shrinks the edge of the tumour, and patients whose disease has not spread go on to surgery with a better chance of a clean removal."},{"label":"Resectable pancreatic ductal adenocarcinoma","href":"/cancers/resectable-pdac/","tip":"Resectable pancreatic cancer is the minority of pancreatic cancer that the surgeon can remove with clear margins because it has not wrapped around the main arteries or spread. Treatment is an operation, usually a Whipple procedure, followed by six months of combination chemotherapy, which is what turns surgery alone into a real chance of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06770439","name":"IBI343 Combined With Chemotherapy in Advanced Pancreatic Cancer","tldr":"A phase 2 trial of IBI343, gemcitabine and nab-paclitaxel in pancreatic cancer, run by Zhejiang University, now recruiting.","route":"/trials/nct06770439/","status":"recruiting","kind":"trial","cancerIcon":"locally-advanced-pdac","sub":"NCT06770439","facets":{"kind":["Trial"],"cancers":["Locally advanced unresectable pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07692750","name":"IBI343 Combined With Chemotherapy in Advanced Pancreatic Cancer","tldr":"A phase 1/2 trial of IBI343, capecitabine and cAPOX (capecitabine, oxaliplatin) in pancreatic cancer, run by Zhejiang Cancer Hospital, now recruiting.","route":"/trials/nct07692750/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-pdac","sub":"NCT07692750","facets":{"kind":["Trial"],"cancers":["Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03608631","name":"iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation","tldr":"A phase 1/2 trial in pancreatic cancer, run by M.D. Anderson Cancer Center, now recruiting.","route":"/trials/nct03608631/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-pdac","sub":"NCT03608631","facets":{"kind":["Trial"],"cancers":["Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06999512","name":"Impact of Comprehensive Geriatric Management on Morbidity and Quality of Life in Elderly Patients Undergoing Major Hepatectomy and Pancreaticoduodenectomy for C","tldr":"A phase 2/3 trial in pancreatic cancer, run by Assistance Publique - Hôpitaux de Paris, not yet recruiting.","route":"/trials/nct06999512/","status":"planned","kind":"trial","cancerIcon":"resectable-pdac","sub":"NCT06999512","facets":{"kind":["Trial"],"cancers":["Resectable pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Resectable pancreatic ductal adenocarcinoma","href":"/cancers/resectable-pdac/","tip":"Resectable pancreatic cancer is the minority of pancreatic cancer that the surgeon can remove with clear margins because it has not wrapped around the main arteries or spread. Treatment is an operation, usually a Whipple procedure, followed by six months of combination chemotherapy, which is what turns surgery alone into a real chance of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05744219","name":"Improved Recovery by Iron Following Surgery With Blood Loss, the IRIS-trial","tldr":"A phase 3 trial in pancreatic cancer, run by Jon Unosson, now recruiting.","route":"/trials/nct05744219/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-pdac","sub":"NCT05744219","facets":{"kind":["Trial"],"cancers":["Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07539155","name":"Intratumoral MMR Vaccine Injection in Borderline Resectable/Unresectable Pancreatic Cancer","tldr":"A phase 1/2 trial in pancreatic cancer, run by University of Arkansas, now recruiting.","route":"/trials/nct07539155/","status":"recruiting","kind":"trial","cancerIcon":"borderline-resectable-pdac","sub":"NCT07539155","facets":{"kind":["Trial"],"cancers":["Borderline resectable pancreatic ductal adenocarcinoma","Locally advanced unresectable pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Borderline resectable pancreatic ductal adenocarcinoma","href":"/cancers/borderline-resectable-pdac/","tip":"Borderline resectable pancreatic cancer touches the big blood vessels behind the pancreas, so an operation straight away would probably leave cancer behind. Chemotherapy first, usually FOLFIRINOX for several months and sometimes radiotherapy, shrinks the edge of the tumour, and patients whose disease has not spread go on to surgery with a better chance of a clean removal."},{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05518903","name":"Investigational Scan (68Ga-FAPI-46 PET/CT) for Imaging of Cancer-Associated Fibroblasts for Localized Pancreatic Ductal Adenocarcinoma","tldr":"A phase 2 trial in pancreatic cancer, run by Mayo Clinic, now recruiting.","route":"/trials/nct05518903/","status":"recruiting","kind":"trial","cancerIcon":"resectable-pdac","sub":"NCT05518903","facets":{"kind":["Trial"],"cancers":["Resectable pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Resectable pancreatic ductal adenocarcinoma","href":"/cancers/resectable-pdac/","tip":"Resectable pancreatic cancer is the minority of pancreatic cancer that the surgeon can remove with clear margins because it has not wrapped around the main arteries or spread. Treatment is an operation, usually a Whipple procedure, followed by six months of combination chemotherapy, which is what turns surgery alone into a real chance of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07306273","name":"IRE Combined With the Dual-Function Antibody PD-1/CTLA-4 for the Treatment of LAPC Following Failure of First-Line AG Therapy","tldr":"A phase 2 trial in pancreatic cancer, run by Ruijin Hospital, now recruiting.","route":"/trials/nct07306273/","status":"recruiting","kind":"trial","cancerIcon":"locally-advanced-pdac","sub":"NCT07306273","facets":{"kind":["Trial"],"cancers":["Locally advanced unresectable pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06172036","name":"Irinotecan Liposome for Resectable Pancreatic Cancer With or Without Addebelizumab","tldr":"A phase 2 trial of cAPOX (capecitabine, oxaliplatin), fluorouracil (5-FU) and leucovorin (folinic acid) in pancreatic cancer, run by Zhejiang University, not yet recruiting.","route":"/trials/nct06172036/","status":"planned","kind":"trial","cancerIcon":"resectable-pdac","sub":"NCT06172036","facets":{"kind":["Trial"],"cancers":["Resectable pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Resectable pancreatic ductal adenocarcinoma","href":"/cancers/resectable-pdac/","tip":"Resectable pancreatic cancer is the minority of pancreatic cancer that the surgeon can remove with clear margins because it has not wrapped around the main arteries or spread. Treatment is an operation, usually a Whipple procedure, followed by six months of combination chemotherapy, which is what turns surgery alone into a real chance of cure."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06513455","name":"Irinotecan Liposome，Albumin Paclitaxel and Gemcitabine First-line Treatment for Pancreatic Cancer","tldr":"A phase 1/2 trial of nab-paclitaxel and gemcitabine in pancreatic cancer, run by Harbin Medical University, not yet recruiting.","route":"/trials/nct06513455/","status":"planned","kind":"trial","cancerIcon":"locally-advanced-pdac","sub":"NCT06513455","facets":{"kind":["Trial"],"cancers":["Locally advanced unresectable pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05720338","name":"Is Intraperitoneal Drainage Necessary Following Distal Pancreatectomy?","tldr":"A phase 3 trial in pancreatic cancer, run by Case Comprehensive Cancer Center, now recruiting.","route":"/trials/nct05720338/","status":"recruiting","kind":"trial","cancerIcon":"resectable-pdac","sub":"NCT05720338","facets":{"kind":["Trial"],"cancers":["Resectable pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Resectable pancreatic ductal adenocarcinoma","href":"/cancers/resectable-pdac/","tip":"Resectable pancreatic cancer is the minority of pancreatic cancer that the surgeon can remove with clear margins because it has not wrapped around the main arteries or spread. Treatment is an operation, usually a Whipple procedure, followed by six months of combination chemotherapy, which is what turns surgery alone into a real chance of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06991491","name":"Ivonescimab With GnP and SBRT in Patients With Metastatic Pancreatic Cancer (WGOG-PAN 004)","tldr":"A phase 2 trial of ivonescimab in pancreatic cancer, run by West China Hospital, not yet recruiting.","route":"/trials/nct06991491/","status":"planned","kind":"trial","cancerIcon":"metastatic-pdac","sub":"NCT06991491","facets":{"kind":["Trial"],"cancers":["Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06491472","name":"Ivonescimab(AK112/SMT112) in Combination With Stereotactic Body Radiation Therapy and Chemotherapy in Patients With Pancreatic Cancer","tldr":"A phase 2 trial of ivonescimab, gemcitabine and nab-paclitaxel in pancreatic cancer, run by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, now recruiting.","route":"/trials/nct06491472/","status":"recruiting","kind":"trial","cancerIcon":"pancreatic","sub":"NCT06491472","facets":{"kind":["Trial"],"cancers":["Pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07175389","name":"JDB153 Combined With Serplulimab for Pancreatic Cancer After Standard Treatment Failure","tldr":"A phase 1/2 trial of serplulimab in pancreatic cancer, run by West China Hospital, not yet recruiting.","route":"/trials/nct07175389/","status":"planned","kind":"trial","cancerIcon":"locally-advanced-pdac","sub":"NCT07175389","facets":{"kind":["Trial"],"cancers":["Locally advanced unresectable pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07353645","name":"KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer","tldr":"A phase 1/2 trial in pancreatic cancer, run by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, now recruiting.","route":"/trials/nct07353645/","status":"recruiting","kind":"trial","cancerIcon":"resectable-pdac","sub":"NCT07353645","facets":{"kind":["Trial"],"cancers":["Resectable pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Resectable pancreatic ductal adenocarcinoma","href":"/cancers/resectable-pdac/","tip":"Resectable pancreatic cancer is the minority of pancreatic cancer that the surgeon can remove with clear margins because it has not wrapped around the main arteries or spread. Treatment is an operation, usually a Whipple procedure, followed by six months of combination chemotherapy, which is what turns surgery alone into a real chance of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06807437","name":"Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula","tldr":"A phase 3 trial of somatostatin analogues (octreotide, lanreotide) in pancreatic cancer, run by SWOG Cancer Research Network, now recruiting.","route":"/trials/nct06807437/","status":"recruiting","kind":"trial","cancerIcon":"resectable-pdac","sub":"NCT06807437","facets":{"kind":["Trial"],"cancers":["Resectable pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Resectable pancreatic ductal adenocarcinoma","href":"/cancers/resectable-pdac/","tip":"Resectable pancreatic cancer is the minority of pancreatic cancer that the surgeon can remove with clear margins because it has not wrapped around the main arteries or spread. Treatment is an operation, usually a Whipple procedure, followed by six months of combination chemotherapy, which is what turns surgery alone into a real chance of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07312422","name":"LDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A Single-Arm Study","tldr":"A phase 1/2 trial of pucotenlimab and gemcitabine + nab-paclitaxel in pancreatic cancer, run by Zhejiang Provincial People's Hospital, now recruiting.","route":"/trials/nct07312422/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-pdac","sub":"NCT07312422","facets":{"kind":["Trial"],"cancers":["Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06229340","name":"Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations","tldr":"A phase 2 trial in pancreatic cancer, run by N.N. Petrov National Medical Research Center of Oncology, now recruiting.","route":"/trials/nct06229340/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-pdac","sub":"NCT06229340","facets":{"kind":["Trial"],"cancers":["Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06782685","name":"Liposomal Irinotecan + Oxaliplatin + Bevacizumab Versus Liposomal Irinotecan + 5-FU/LV","tldr":"A phase 1/2 trial of cAPOX (capecitabine, oxaliplatin), bevacizumab, fluorouracil (5-FU) and leucovorin (folinic acid) in pancreatic cancer, run by Dai, Guanghai, now recruiting.","route":"/trials/nct06782685/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-pdac","sub":"NCT06782685","facets":{"kind":["Trial"],"cancers":["Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06571461","name":"Liposomal Irinotecan in Combination With Oxaliplatin and S-1 Versus Gemcitabine Combined With Capecitabine as Postoperative Adjuvant Therapy for Pancreatic Canc","tldr":"A phase 3 trial of liposomal irinotecan, cAPOX (capecitabine, oxaliplatin), tegafur, gimeracil and oteracil (S-1), gemcitabine and other drugs in pancreatic cancer, run by CSPC Ouyi Pharmaceutical Co., Ltd., not yet recruiting.","route":"/trials/nct06571461/","status":"planned","kind":"trial","cancerIcon":"resectable-pdac","sub":"NCT06571461","facets":{"kind":["Trial"],"cancers":["Resectable pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Resectable pancreatic ductal adenocarcinoma","href":"/cancers/resectable-pdac/","tip":"Resectable pancreatic cancer is the minority of pancreatic cancer that the surgeon can remove with clear margins because it has not wrapped around the main arteries or spread. Treatment is an operation, usually a Whipple procedure, followed by six months of combination chemotherapy, which is what turns surgery alone into a real chance of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07542002","name":"Liposomal Irinotecan, 5-fluorouracil/Calcium Folinate, Oxaliplatin, and Adebrelimab in Combination With Radiotherapy for Resectable or Borderline Resectable Pan","tldr":"A phase 2 trial of fLOT (5-FU, leucovorin, oxaliplatin, docetaxel) and cAPOX (capecitabine, oxaliplatin) in pancreatic cancer, run by Ningbo Medical Center Lihuili Hospital, now recruiting.","route":"/trials/nct07542002/","status":"recruiting","kind":"trial","cancerIcon":"borderline-resectable-pdac","sub":"NCT07542002","facets":{"kind":["Trial"],"cancers":["Borderline resectable pancreatic ductal adenocarcinoma","Resectable pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Borderline resectable pancreatic ductal adenocarcinoma","href":"/cancers/borderline-resectable-pdac/","tip":"Borderline resectable pancreatic cancer touches the big blood vessels behind the pancreas, so an operation straight away would probably leave cancer behind. Chemotherapy first, usually FOLFIRINOX for several months and sometimes radiotherapy, shrinks the edge of the tumour, and patients whose disease has not spread go on to surgery with a better chance of a clean removal."},{"label":"Resectable pancreatic ductal adenocarcinoma","href":"/cancers/resectable-pdac/","tip":"Resectable pancreatic cancer is the minority of pancreatic cancer that the surgeon can remove with clear margins because it has not wrapped around the main arteries or spread. Treatment is an operation, usually a Whipple procedure, followed by six months of combination chemotherapy, which is what turns surgery alone into a real chance of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06391892","name":"Liquid Biopsy (ctDNA) Guided Treatment in Localized Pancreatic Cancer: Neoadjuvant CTX vs. Upfront Surgery","tldr":"A phase 3 trial in pancreatic cancer, run by Elisabethinen Hospital, now recruiting.","route":"/trials/nct06391892/","status":"recruiting","kind":"trial","cancerIcon":"resectable-pdac","sub":"NCT06391892","facets":{"kind":["Trial"],"cancers":["Resectable pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Resectable pancreatic ductal adenocarcinoma","href":"/cancers/resectable-pdac/","tip":"Resectable pancreatic cancer is the minority of pancreatic cancer that the surgeon can remove with clear margins because it has not wrapped around the main arteries or spread. Treatment is an operation, usually a Whipple procedure, followed by six months of combination chemotherapy, which is what turns surgery alone into a real chance of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07199764","name":"Maintenance Combinatorial Myeloid Immunotherapy for Unresectable Pancreatic Cancer","tldr":"A phase 2 trial of mitazalimab in pancreatic cancer, run by University of Pennsylvania, now recruiting.","route":"/trials/nct07199764/","status":"recruiting","kind":"trial","cancerIcon":"locally-advanced-pdac","sub":"NCT07199764","facets":{"kind":["Trial"],"cancers":["Locally advanced unresectable pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06747845","name":"Maintenance Niraparib Plus Ipilimumab in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on Platinum-Based Chemotherapy","tldr":"A phase 2 trial of niraparib and ipilimumab in pancreatic cancer, run by Abramson Cancer Center at Penn Medicine, now recruiting.","route":"/trials/nct06747845/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-pdac","sub":"NCT06747845","facets":{"kind":["Trial"],"cancers":["Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06605430","name":"Medical Cannabis in Patients With Advanced Pancreatic and Colorectal Cancer","tldr":"A phase 2 trial in pancreatic cancer, run by HealthPartners Institute, now recruiting.","route":"/trials/nct06605430/","status":"recruiting","kind":"trial","cancerIcon":"locally-advanced-pdac","sub":"NCT06605430","facets":{"kind":["Trial"],"cancers":["Locally advanced unresectable pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07066995","name":"Mesothelin and Claudin 18.2 Dual-Target CAR-T Therapy in Advanced Pancreatic Cancer","tldr":"A phase 1/2 trial of EB-MF-CAR-NK-01 in pancreatic cancer, run by Essen Biotech, now recruiting.","route":"/trials/nct07066995/","status":"recruiting","kind":"trial","cancerIcon":"locally-advanced-pdac","sub":"NCT07066995","facets":{"kind":["Trial"],"cancers":["Locally advanced unresectable pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07344220","name":"Metastatic Non-Familial Adenocarcinoma Maintenance Therapy With DZ-002: Heptamine Carboxymethine Dye Conjugate","tldr":"A phase 2 trial in pancreatic cancer, run by Hoag Memorial Hospital Presbyterian, now recruiting.","route":"/trials/nct07344220/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-pdac","sub":"NCT07344220","facets":{"kind":["Trial"],"cancers":["Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06759090","name":"Metronomic Capecitabine with Camrelizumab and Apatinib Mesylate for Treatment of Advanced Pancreatic Cancer","tldr":"A phase 2 trial of camrelizumab in pancreatic cancer, run by Zhejiang University, not yet recruiting.","route":"/trials/nct06759090/","status":"planned","kind":"trial","cancerIcon":"metastatic-pdac","sub":"NCT06759090","facets":{"kind":["Trial"],"cancers":["Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05929885","name":"Metronomic Capecitabine, Oxaliplatin and UGT1A1 Genotype-directed Irinotecan in Metastatic Pancreatic Cancer Patients","tldr":"A phase 2 trial in pancreatic cancer, run by National Cancer Centre, Singapore, now recruiting.","route":"/trials/nct05929885/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-pdac","sub":"NCT05929885","facets":{"kind":["Trial"],"cancers":["Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04084496","name":"mFOLFIRINOX as Adjuvent Chemotherapy in Treating Chinese Pancreatic Cancer Patients","tldr":"A phase 2 trial of fOLFIRINOX / mFOLFIRINOX in pancreatic cancer, run by Sun Yat-sen University, now recruiting.","route":"/trials/nct04084496/","status":"recruiting","kind":"trial","cancerIcon":"resectable-pdac","sub":"NCT04084496","facets":{"kind":["Trial"],"cancers":["Resectable pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Resectable pancreatic ductal adenocarcinoma","href":"/cancers/resectable-pdac/","tip":"Resectable pancreatic cancer is the minority of pancreatic cancer that the surgeon can remove with clear margins because it has not wrapped around the main arteries or spread. Treatment is an operation, usually a Whipple procedure, followed by six months of combination chemotherapy, which is what turns surgery alone into a real chance of cure."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06761027","name":"mFOLFIRINOX Plus Anlotinib and Sintilimab for Advanced Pancreatic Cancer","tldr":"A phase 1/2 trial of anlotinib and sintilimab in pancreatic cancer, run by Fujian Provincial Hospital, now recruiting.","route":"/trials/nct06761027/","status":"recruiting","kind":"trial","cancerIcon":"locally-advanced-pdac","sub":"NCT06761027","facets":{"kind":["Trial"],"cancers":["Locally advanced unresectable pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06149689","name":"mFOLFIRINOX Plus Radiotherapy to Patients With CA19-9-normal Advanced Pancreatic Cancer","tldr":"A phase 2 trial in pancreatic cancer, run by Fudan University, now recruiting.","route":"/trials/nct06149689/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-pdac","sub":"NCT06149689","facets":{"kind":["Trial"],"cancers":["Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06249321","name":"mFOLFIRINOX Plus Radiotherapy to Patients With CA19-9-normal Advanced Pancreatic Cancer Refractory to Chemotherapy","tldr":"A phase 2 trial in pancreatic cancer, run by Fudan University, now recruiting.","route":"/trials/nct06249321/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-pdac","sub":"NCT06249321","facets":{"kind":["Trial"],"cancers":["Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05462496","name":"Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer","tldr":"A phase 2 trial of fOLFIRINOX / mFOLFIRINOX and pembrolizumab in pancreatic cancer, run by Icahn School of Medicine at Mount Sinai, now recruiting.","route":"/trials/nct05462496/","status":"recruiting","kind":"trial","cancerIcon":"resectable-pdac","sub":"NCT05462496","facets":{"kind":["Trial"],"cancers":["Resectable pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Resectable pancreatic ductal adenocarcinoma","href":"/cancers/resectable-pdac/","tip":"Resectable pancreatic cancer is the minority of pancreatic cancer that the surgeon can remove with clear margins because it has not wrapped around the main arteries or spread. Treatment is an operation, usually a Whipple procedure, followed by six months of combination chemotherapy, which is what turns surgery alone into a real chance of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07802418","name":"Molecularly Tailored Therapy in Advanced Pancreatic Cancer","tldr":"A phase 2 trial in pancreatic cancer, run by Herlev Hospital, not yet recruiting.","route":"/trials/nct07802418/","status":"planned","kind":"trial","cancerIcon":"metastatic-pdac","sub":"NCT07802418","facets":{"kind":["Trial"],"cancers":["Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06782412","name":"Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Dif","tldr":"A phase 2/3 trial in pancreatic cancer, run by KU Leuven, now recruiting.","route":"/trials/nct06782412/","status":"recruiting","kind":"trial","cancerIcon":"pancreatic","sub":"NCT06782412","facets":{"kind":["Trial"],"cancers":["Pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04146298","name":"Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer","tldr":"A phase 1/2 trial of cyclophosphamide and fludarabine in pancreatic cancer, run by Changhai Hospital, now recruiting.","route":"/trials/nct04146298/","status":"recruiting","kind":"trial","cancerIcon":"resectable-pdac","sub":"NCT04146298","facets":{"kind":["Trial"],"cancers":["Resectable pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Resectable pancreatic ductal adenocarcinoma","href":"/cancers/resectable-pdac/","tip":"Resectable pancreatic cancer is the minority of pancreatic cancer that the surgeon can remove with clear margins because it has not wrapped around the main arteries or spread. Treatment is an operation, usually a Whipple procedure, followed by six months of combination chemotherapy, which is what turns surgery alone into a real chance of cure."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04605913","name":"Nab-Paclitaxel + Cisplatin + Gemcitabine + TTF in pt. w/ Metastatic PAC","tldr":"A phase 1/2 trial in pancreatic cancer, run by Mayo Clinic, now recruiting.","route":"/trials/nct04605913/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-pdac","sub":"NCT04605913","facets":{"kind":["Trial"],"cancers":["Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06662006","name":"Nal-IRI/5-FU/LV Chemotherapy Combined With PD-L1 Inhibitor and Multi-target Anti-angiogenic Small Molecule±SBRT as Second-line Therapy in Metastatic Pancreatic","tldr":"A phase 2 trial in pancreatic cancer, run by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, now recruiting.","route":"/trials/nct06662006/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-pdac","sub":"NCT06662006","facets":{"kind":["Trial"],"cancers":["Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06405490","name":"NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC","tldr":"A phase 2 trial of cAPOX (capecitabine, oxaliplatin), capecitabine and cadonilimab in pancreatic cancer, run by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, now recruiting.","route":"/trials/nct06405490/","status":"recruiting","kind":"trial","cancerIcon":"locally-advanced-pdac","sub":"NCT06405490","facets":{"kind":["Trial"],"cancers":["Locally advanced unresectable pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06669078","name":"NALIRIFOX Combined With PD-1 Sequential Radiotherapy Versus NALIRIFOX as Conversion Therapy of Locally Advanced Pancreatic Cancer","tldr":"A phase 2 trial of fluorouracil (5-FU) in pancreatic cancer, run by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, not yet recruiting.","route":"/trials/nct06669078/","status":"planned","kind":"trial","cancerIcon":"locally-advanced-pdac","sub":"NCT06669078","facets":{"kind":["Trial"],"cancers":["Locally advanced unresectable pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07595172","name":"NALIRIFOX+Adebrelimab+PULSAR for Advanced Pancreatic Cancer","tldr":"A phase 1/2 trial in pancreatic cancer, run by West China Hospital, now recruiting.","route":"/trials/nct07595172/","status":"recruiting","kind":"trial","cancerIcon":"locally-advanced-pdac","sub":"NCT07595172","facets":{"kind":["Trial"],"cancers":["Locally advanced unresectable pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04789486","name":"Nano-SMART: Nanoparticles With MR Guided SBRT in Centrally Located Lung Tumors and Pancreatic Cancer","tldr":"A phase 1/2 trial in pancreatic cancer, run by Dana-Farber Cancer Institute, now recruiting.","route":"/trials/nct04789486/","status":"recruiting","kind":"trial","cancerIcon":"locally-advanced-pdac","sub":"NCT04789486","facets":{"kind":["Trial"],"cancers":["Locally advanced unresectable pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06941857","name":"NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer","tldr":"A phase 2 trial of cAPOX (capecitabine, oxaliplatin), fOLFIRI (5-FU, leucovorin, irinotecan), leucovorin (folinic acid), fluorouracil (5-FU) and other drugs in pancreatic cancer, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, now recruiting.","route":"/trials/nct06941857/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-pdac","sub":"NCT06941857","facets":{"kind":["Trial"],"cancers":["Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07824960","name":"Neoadjuvant Avutometinib/Defactinib and mFOLFIRINOX Combination Therapy in Pancreatic Adenocarcinoma","tldr":"A phase 1/2 trial of avutometinib + defactinib in pancreatic cancer, run by University of Virginia, not yet recruiting.","route":"/trials/nct07824960/","status":"planned","kind":"trial","cancerIcon":"resectable-pdac","sub":"NCT07824960","facets":{"kind":["Trial"],"cancers":["Resectable pancreatic ductal adenocarcinoma","Locally advanced unresectable pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Resectable pancreatic ductal adenocarcinoma","href":"/cancers/resectable-pdac/","tip":"Resectable pancreatic cancer is the minority of pancreatic cancer that the surgeon can remove with clear margins because it has not wrapped around the main arteries or spread. Treatment is an operation, usually a Whipple procedure, followed by six months of combination chemotherapy, which is what turns surgery alone into a real chance of cure."},{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05268692","name":"Neoadjuvant Chemotherapy for Pancreatic Cancer Followed by GS and GnP","tldr":"A phase 2/3 trial of gemcitabine + nab-paclitaxel in pancreatic cancer, run by Kochi University, now recruiting.","route":"/trials/nct05268692/","status":"recruiting","kind":"trial","cancerIcon":"resectable-pdac","sub":"NCT05268692","facets":{"kind":["Trial"],"cancers":["Resectable pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Resectable pancreatic ductal adenocarcinoma","href":"/cancers/resectable-pdac/","tip":"Resectable pancreatic cancer is the minority of pancreatic cancer that the surgeon can remove with clear margins because it has not wrapped around the main arteries or spread. Treatment is an operation, usually a Whipple procedure, followed by six months of combination chemotherapy, which is what turns surgery alone into a real chance of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05132504","name":"Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer","tldr":"A phase 2 trial of pembrolizumab and fOLFIRINOX / mFOLFIRINOX in pancreatic cancer, run by Baylor College of Medicine, now recruiting.","route":"/trials/nct05132504/","status":"recruiting","kind":"trial","cancerIcon":"resectable-pdac","sub":"NCT05132504","facets":{"kind":["Trial"],"cancers":["Resectable pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Resectable pancreatic ductal adenocarcinoma","href":"/cancers/resectable-pdac/","tip":"Resectable pancreatic cancer is the minority of pancreatic cancer that the surgeon can remove with clear margins because it has not wrapped around the main arteries or spread. Treatment is an operation, usually a Whipple procedure, followed by six months of combination chemotherapy, which is what turns surgery alone into a real chance of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07691593","name":"Neoadjuvant HRS-4642 Plus Chemotherapy With or Without Immunotherapy for Pancreatic Cancer","tldr":"A phase 2 trial in pancreatic cancer, run by Changhai Hospital, not yet recruiting.","route":"/trials/nct07691593/","status":"planned","kind":"trial","cancerIcon":"resectable-pdac","sub":"NCT07691593","facets":{"kind":["Trial"],"cancers":["Resectable pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Resectable pancreatic ductal adenocarcinoma","href":"/cancers/resectable-pdac/","tip":"Resectable pancreatic cancer is the minority of pancreatic cancer that the surgeon can remove with clear margins because it has not wrapped around the main arteries or spread. Treatment is an operation, usually a Whipple procedure, followed by six months of combination chemotherapy, which is what turns surgery alone into a real chance of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07155629","name":"Neoadjuvant Treatment vs Upfront Surgery for Left-Sided Pancreatic Cancer","tldr":"A phase 3 trial in pancreatic cancer, run by Helsinki University Central Hospital, not yet recruiting.","route":"/trials/nct07155629/","status":"planned","kind":"trial","cancerIcon":"resectable-pdac","sub":"NCT07155629","facets":{"kind":["Trial"],"cancers":["Resectable pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Resectable pancreatic ductal adenocarcinoma","href":"/cancers/resectable-pdac/","tip":"Resectable pancreatic cancer is the minority of pancreatic cancer that the surgeon can remove with clear margins because it has not wrapped around the main arteries or spread. Treatment is an operation, usually a Whipple procedure, followed by six months of combination chemotherapy, which is what turns surgery alone into a real chance of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06384560","name":"Neoadjuvant Triple Therapy for (Borderline) Resectable Pancreatic Cancer (PREOPANC-5)","tldr":"A phase 1/2 trial of pembrolizumab and fOLFIRINOX / mFOLFIRINOX in pancreatic cancer, run by Amsterdam UMC, location VUmc, now recruiting.","route":"/trials/nct06384560/","status":"recruiting","kind":"trial","cancerIcon":"borderline-resectable-pdac","sub":"NCT06384560","facets":{"kind":["Trial"],"cancers":["Borderline resectable pancreatic ductal adenocarcinoma","Resectable pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Borderline resectable pancreatic ductal adenocarcinoma","href":"/cancers/borderline-resectable-pdac/","tip":"Borderline resectable pancreatic cancer touches the big blood vessels behind the pancreas, so an operation straight away would probably leave cancer behind. Chemotherapy first, usually FOLFIRINOX for several months and sometimes radiotherapy, shrinks the edge of the tumour, and patients whose disease has not spread go on to surgery with a better chance of a clean removal."},{"label":"Resectable pancreatic ductal adenocarcinoma","href":"/cancers/resectable-pdac/","tip":"Resectable pancreatic cancer is the minority of pancreatic cancer that the surgeon can remove with clear margins because it has not wrapped around the main arteries or spread. Treatment is an operation, usually a Whipple procedure, followed by six months of combination chemotherapy, which is what turns surgery alone into a real chance of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07081360","name":"Neoadjuvant vs Upfront Surgery for Resectable Pancreatic Cancer and Periampullary Cancer","tldr":"A phase 3 trial in pancreatic cancer, run by Minia University, now recruiting.","route":"/trials/nct07081360/","status":"recruiting","kind":"trial","cancerIcon":"resectable-pdac","sub":"NCT07081360","facets":{"kind":["Trial"],"cancers":["Resectable pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Resectable pancreatic ductal adenocarcinoma","href":"/cancers/resectable-pdac/","tip":"Resectable pancreatic cancer is the minority of pancreatic cancer that the surgeon can remove with clear margins because it has not wrapped around the main arteries or spread. Treatment is an operation, usually a Whipple procedure, followed by six months of combination chemotherapy, which is what turns surgery alone into a real chance of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05562297","name":"Neoadjuvant/Adjuvant Sintilimab, Nab-paclitaxel, and Gemcitabine for Resectable/Borderline Resectable Pancreatic Cancer","tldr":"A phase 2 trial of sintilimab, nab-paclitaxel and gemcitabine in pancreatic cancer, run by Shanghai Zhongshan Hospital, not yet recruiting.","route":"/trials/nct05562297/","status":"planned","kind":"trial","cancerIcon":"borderline-resectable-pdac","sub":"NCT05562297","facets":{"kind":["Trial"],"cancers":["Borderline resectable pancreatic ductal adenocarcinoma","Resectable pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Borderline resectable pancreatic ductal adenocarcinoma","href":"/cancers/borderline-resectable-pdac/","tip":"Borderline resectable pancreatic cancer touches the big blood vessels behind the pancreas, so an operation straight away would probably leave cancer behind. Chemotherapy first, usually FOLFIRINOX for several months and sometimes radiotherapy, shrinks the edge of the tumour, and patients whose disease has not spread go on to surgery with a better chance of a clean removal."},{"label":"Resectable pancreatic ductal adenocarcinoma","href":"/cancers/resectable-pdac/","tip":"Resectable pancreatic cancer is the minority of pancreatic cancer that the surgeon can remove with clear margins because it has not wrapped around the main arteries or spread. Treatment is an operation, usually a Whipple procedure, followed by six months of combination chemotherapy, which is what turns surgery alone into a real chance of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05529940","name":"NeoFOL-R Trial (Perioperative Versus Adjuvnat FOLFIRINOX in Resectable Pancreatic Cancer)","tldr":"A phase 3 trial of fOLFIRINOX / mFOLFIRINOX in pancreatic cancer, run by Seoul National University Hospital, now recruiting.","route":"/trials/nct05529940/","status":"recruiting","kind":"trial","cancerIcon":"resectable-pdac","sub":"NCT05529940","facets":{"kind":["Trial"],"cancers":["Resectable pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Resectable pancreatic ductal adenocarcinoma","href":"/cancers/resectable-pdac/","tip":"Resectable pancreatic cancer is the minority of pancreatic cancer that the surgeon can remove with clear margins because it has not wrapped around the main arteries or spread. Treatment is an operation, usually a Whipple procedure, followed by six months of combination chemotherapy, which is what turns surgery alone into a real chance of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06370754","name":"Newly Emerging Immunotherapy for Pancreatic Cancer Treatment","tldr":"A phase 1/2 trial of liposomal irinotecan, fluorouracil (5-FU), fLOT (5-FU, leucovorin, oxaliplatin, docetaxel), nab-paclitaxel and other drugs in pancreatic cancer, run by Fudan University, not yet recruiting.","route":"/trials/nct06370754/","status":"planned","kind":"trial","cancerIcon":"locally-advanced-pdac","sub":"NCT06370754","facets":{"kind":["Trial"],"cancers":["Locally advanced unresectable pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07386704","name":"Nimotuzumab Combined With Chemoradiotherapy in the Treatment of Unresectable Locally Advanced or Oligometastatic Pancreatic Cancer","tldr":"A phase 2 trial of nimotuzumab in pancreatic cancer, run by Peking University First Hospital, now recruiting.","route":"/trials/nct07386704/","status":"recruiting","kind":"trial","cancerIcon":"locally-advanced-pdac","sub":"NCT07386704","facets":{"kind":["Trial"],"cancers":["Locally advanced unresectable pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06409429","name":"Nimotuzumab Combined With GX as Postoperative Adjuvant Therapy in Pancreatic Cancer","tldr":"A phase 2/3 trial of nimotuzumab in pancreatic cancer, run by Tianjin Medical University Cancer Institute and Hospital, not yet recruiting.","route":"/trials/nct06409429/","status":"planned","kind":"trial","cancerIcon":"resectable-pdac","sub":"NCT06409429","facets":{"kind":["Trial"],"cancers":["Resectable pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Resectable pancreatic ductal adenocarcinoma","href":"/cancers/resectable-pdac/","tip":"Resectable pancreatic cancer is the minority of pancreatic cancer that the surgeon can remove with clear margins because it has not wrapped around the main arteries or spread. Treatment is an operation, usually a Whipple procedure, followed by six months of combination chemotherapy, which is what turns surgery alone into a real chance of cure."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06389760","name":"Nimotuzumab Combined With mFOLFIRINOX/GX as Postoperative Adjuvant Therapy in Pancreatic Cancer","tldr":"A phase 2 trial of nimotuzumab and fOLFIRINOX / mFOLFIRINOX in pancreatic cancer, run by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, now recruiting.","route":"/trials/nct06389760/","status":"recruiting","kind":"trial","cancerIcon":"resectable-pdac","sub":"NCT06389760","facets":{"kind":["Trial"],"cancers":["Resectable pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Resectable pancreatic ductal adenocarcinoma","href":"/cancers/resectable-pdac/","tip":"Resectable pancreatic cancer is the minority of pancreatic cancer that the surgeon can remove with clear margins because it has not wrapped around the main arteries or spread. Treatment is an operation, usually a Whipple procedure, followed by six months of combination chemotherapy, which is what turns surgery alone into a real chance of cure."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07277452","name":"Nimotuzumab Combined With Nab-paclitaxel/Gemcitabine in the Perioperative Treatment of High-risk Resectable/Borderline Resectable Pancreatic Cancer","tldr":"A phase 2 trial of nimotuzumab and gemcitabine + nab-paclitaxel in pancreatic cancer, run by The First Affiliated Hospital with Nanjing Medical University, not yet recruiting.","route":"/trials/nct07277452/","status":"planned","kind":"trial","cancerIcon":"borderline-resectable-pdac","sub":"NCT07277452","facets":{"kind":["Trial"],"cancers":["Borderline resectable pancreatic ductal adenocarcinoma","Resectable pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Borderline resectable pancreatic ductal adenocarcinoma","href":"/cancers/borderline-resectable-pdac/","tip":"Borderline resectable pancreatic cancer touches the big blood vessels behind the pancreas, so an operation straight away would probably leave cancer behind. Chemotherapy first, usually FOLFIRINOX for several months and sometimes radiotherapy, shrinks the edge of the tumour, and patients whose disease has not spread go on to surgery with a better chance of a clean removal."},{"label":"Resectable pancreatic ductal adenocarcinoma","href":"/cancers/resectable-pdac/","tip":"Resectable pancreatic cancer is the minority of pancreatic cancer that the surgeon can remove with clear margins because it has not wrapped around the main arteries or spread. Treatment is an operation, usually a Whipple procedure, followed by six months of combination chemotherapy, which is what turns surgery alone into a real chance of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05984810","name":"NIR-Fluorescence Guided Surgical Resection of Neoadjuvant Treated Localized Pancreatic Cancer Using SGM-101","tldr":"A phase 2 trial in pancreatic cancer, run by Leiden University Medical Center, now recruiting.","route":"/trials/nct05984810/","status":"recruiting","kind":"trial","cancerIcon":"borderline-resectable-pdac","sub":"NCT05984810","facets":{"kind":["Trial"],"cancers":["Borderline resectable pancreatic ductal adenocarcinoma","Resectable pancreatic ductal adenocarcinoma","Locally advanced unresectable pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Borderline resectable pancreatic ductal adenocarcinoma","href":"/cancers/borderline-resectable-pdac/","tip":"Borderline resectable pancreatic cancer touches the big blood vessels behind the pancreas, so an operation straight away would probably leave cancer behind. Chemotherapy first, usually FOLFIRINOX for several months and sometimes radiotherapy, shrinks the edge of the tumour, and patients whose disease has not spread go on to surgery with a better chance of a clean removal."},{"label":"Resectable pancreatic ductal adenocarcinoma","href":"/cancers/resectable-pdac/","tip":"Resectable pancreatic cancer is the minority of pancreatic cancer that the surgeon can remove with clear margins because it has not wrapped around the main arteries or spread. Treatment is an operation, usually a Whipple procedure, followed by six months of combination chemotherapy, which is what turns surgery alone into a real chance of cure."},{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04901741","name":"Olaptesed With Pembrolizumab and Nanoliposomal Irinotecan or Gemcitabine/Nab-Paclitaxel in MSS Pancreatic Cancer","tldr":"A phase 2 trial of pembrolizumab in pancreatic cancer, run by TME Pharma AG, not yet recruiting.","route":"/trials/nct04901741/","status":"planned","kind":"trial","cancerIcon":"metastatic-pdac","sub":"NCT04901741","facets":{"kind":["Trial"],"cancers":["Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06196671","name":"Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer","tldr":"A phase 2 trial of h101 oncolytic adenovirus and camrelizumab in pancreatic cancer, run by Fudan University, not yet recruiting.","route":"/trials/nct06196671/","status":"planned","kind":"trial","cancerIcon":"metastatic-pdac","sub":"NCT06196671","facets":{"kind":["Trial"],"cancers":["Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06904378","name":"ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma","tldr":"A phase 1/2 trial of gemcitabine and nab-paclitaxel in pancreatic cancer, run by Washington University School of Medicine, now recruiting.","route":"/trials/nct06904378/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-pdac","sub":"NCT06904378","facets":{"kind":["Trial"],"cancers":["Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06736717","name":"Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic Cancer","tldr":"A phase 1/2 trial of onvansertib and nALIRIFOX (liposomal irinotecan + oxaliplatin + 5-FU/LV) in pancreatic cancer, run by University of Kansas Medical Center, now recruiting.","route":"/trials/nct06736717/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-pdac","sub":"NCT06736717","facets":{"kind":["Trial"],"cancers":["Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03322995","name":"Pancreatic Cancer Adaptive Neoadjuvant Chemotherapy Trial","tldr":"A phase 2 trial in pancreatic cancer, run by Medical College of Wisconsin, now recruiting.","route":"/trials/nct03322995/","status":"recruiting","kind":"trial","cancerIcon":"borderline-resectable-pdac","sub":"NCT03322995","facets":{"kind":["Trial"],"cancers":["Borderline resectable pancreatic ductal adenocarcinoma","Resectable pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Borderline resectable pancreatic ductal adenocarcinoma","href":"/cancers/borderline-resectable-pdac/","tip":"Borderline resectable pancreatic cancer touches the big blood vessels behind the pancreas, so an operation straight away would probably leave cancer behind. Chemotherapy first, usually FOLFIRINOX for several months and sometimes radiotherapy, shrinks the edge of the tumour, and patients whose disease has not spread go on to surgery with a better chance of a clean removal."},{"label":"Resectable pancreatic ductal adenocarcinoma","href":"/cancers/resectable-pdac/","tip":"Resectable pancreatic cancer is the minority of pancreatic cancer that the surgeon can remove with clear margins because it has not wrapped around the main arteries or spread. Treatment is an operation, usually a Whipple procedure, followed by six months of combination chemotherapy, which is what turns surgery alone into a real chance of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07098598","name":"Pancreatic Cancer Diagnosis With FAPI-PET Imaging","tldr":"A phase 2/3 trial in pancreatic cancer, run by Turku University Hospital, now recruiting.","route":"/trials/nct07098598/","status":"recruiting","kind":"trial","cancerIcon":"pancreatic","sub":"NCT07098598","facets":{"kind":["Trial"],"cancers":["Pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07230509","name":"Pancreatic Parenchymal Injection of N-butyl-2-cyanoacrylate","tldr":"A phase 2 trial in pancreatic cancer, run by Minia University, now recruiting.","route":"/trials/nct07230509/","status":"recruiting","kind":"trial","cancerIcon":"resectable-pdac","sub":"NCT07230509","facets":{"kind":["Trial"],"cancers":["Resectable pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Resectable pancreatic ductal adenocarcinoma","href":"/cancers/resectable-pdac/","tip":"Resectable pancreatic cancer is the minority of pancreatic cancer that the surgeon can remove with clear margins because it has not wrapped around the main arteries or spread. Treatment is an operation, usually a Whipple procedure, followed by six months of combination chemotherapy, which is what turns surgery alone into a real chance of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03384238","name":"Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery","tldr":"A phase 1/2 trial of panitumumab in pancreatic cancer, run by George Poultsides, now recruiting.","route":"/trials/nct03384238/","status":"recruiting","kind":"trial","cancerIcon":"resectable-pdac","sub":"NCT03384238","facets":{"kind":["Trial"],"cancers":["Resectable pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Resectable pancreatic ductal adenocarcinoma","href":"/cancers/resectable-pdac/","tip":"Resectable pancreatic cancer is the minority of pancreatic cancer that the surgeon can remove with clear margins because it has not wrapped around the main arteries or spread. Treatment is an operation, usually a Whipple procedure, followed by six months of combination chemotherapy, which is what turns surgery alone into a real chance of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07028424","name":"PANORAMIX : Optimizing 1st-line NALIRIFOX and Exploring Microbiota's Role in 2nd Line Pancreatic Cancer Treatment","tldr":"A phase 2 trial of liposomal irinotecan, paclitaxel / nab-paclitaxel, gemcitabine, cAPOX (capecitabine, oxaliplatin) and other drugs in pancreatic cancer, run by GERCOR - Multidisciplinary Oncology Cooperative Group, not yet recruiting.","route":"/trials/nct07028424/","status":"planned","kind":"trial","cancerIcon":"metastatic-pdac","sub":"NCT07028424","facets":{"kind":["Trial"],"cancers":["Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06359275","name":"PD-1 Combined With Chemotherapy and PULSAR in LAPC and Local Recurrence Patients","tldr":"A phase 2 trial of nab-paclitaxel and gemcitabine in pancreatic cancer, run by Fudan University, now recruiting.","route":"/trials/nct06359275/","status":"recruiting","kind":"trial","cancerIcon":"locally-advanced-pdac","sub":"NCT06359275","facets":{"kind":["Trial"],"cancers":["Locally advanced unresectable pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07477418","name":"PDAC Regression and Intraoperative Surgical Margin With Neoadjuvant TAMP (PRISM-TAMP)","tldr":"A phase 1/2 trial in pancreatic cancer, run by University of Vermont, not yet recruiting.","route":"/trials/nct07477418/","status":"planned","kind":"trial","cancerIcon":"borderline-resectable-pdac","sub":"NCT07477418","facets":{"kind":["Trial"],"cancers":["Borderline resectable pancreatic ductal adenocarcinoma","Resectable pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Borderline resectable pancreatic ductal adenocarcinoma","href":"/cancers/borderline-resectable-pdac/","tip":"Borderline resectable pancreatic cancer touches the big blood vessels behind the pancreas, so an operation straight away would probably leave cancer behind. Chemotherapy first, usually FOLFIRINOX for several months and sometimes radiotherapy, shrinks the edge of the tumour, and patients whose disease has not spread go on to surgery with a better chance of a clean removal."},{"label":"Resectable pancreatic ductal adenocarcinoma","href":"/cancers/resectable-pdac/","tip":"Resectable pancreatic cancer is the minority of pancreatic cancer that the surgeon can remove with clear margins because it has not wrapped around the main arteries or spread. Treatment is an operation, usually a Whipple procedure, followed by six months of combination chemotherapy, which is what turns surgery alone into a real chance of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07214298","name":"Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma","tldr":"A phase 1/2 trial of fluorouracil (5-FU), fOLFIRI (5-FU, leucovorin, irinotecan), leucovorin (folinic acid) and cAPOX (capecitabine, oxaliplatin) in pancreatic cancer, run by Roswell Park Cancer Institute, now recruiting.","route":"/trials/nct07214298/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-pdac","sub":"NCT07214298","facets":{"kind":["Trial"],"cancers":["Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05093231","name":"Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer","tldr":"A phase 2 trial of pembrolizumab and olaparib in pancreatic cancer, run by Cambridge University Hospitals NHS Foundation Trust, now recruiting.","route":"/trials/nct05093231/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-pdac","sub":"NCT05093231","facets":{"kind":["Trial"],"cancers":["Metastatic pancreatic ductal adenocarcinoma","Mismatch repair deficient (MSI-high) pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."},{"label":"Mismatch repair deficient (MSI-high) pancreatic ductal adenocarcinoma","href":"/cancers/msi-high-pdac/","tip":"Mismatch repair deficient pancreatic cancer is the rare pancreatic cancer whose cells cannot fix spelling errors in DNA and so carry thousands of mutations. That makes it one of the few pancreatic cancers that immunotherapy works against, and pembrolizumab is approved for it, though fewer of these tumours respond than in bowel cancer; testing every pancreatic cancer for the defect is the point."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05637567","name":"Perioperative Platelet Inhibition With Acetylsalicylic Acid in Patients With Resectable Tumors of the Pancreatic Head","tldr":"A phase 2 trial of aspirin in pancreatic cancer, run by German Cancer Research Center, not yet recruiting.","route":"/trials/nct05637567/","status":"planned","kind":"trial","cancerIcon":"resectable-pdac","sub":"NCT05637567","facets":{"kind":["Trial"],"cancers":["Resectable pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Resectable pancreatic ductal adenocarcinoma","href":"/cancers/resectable-pdac/","tip":"Resectable pancreatic cancer is the minority of pancreatic cancer that the surgeon can remove with clear margins because it has not wrapped around the main arteries or spread. Treatment is an operation, usually a Whipple procedure, followed by six months of combination chemotherapy, which is what turns surgery alone into a real chance of cure."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06210360","name":"Perioperative Treatment in High-risk Resectable Pancreatic Cancer With NALIRIFOX","tldr":"A phase 2 trial of liposomal irinotecan, cAPOX (capecitabine, oxaliplatin), fluorouracil (5-FU) and leucovorin (folinic acid) in pancreatic cancer, run by Changhai Hospital, not yet recruiting.","route":"/trials/nct06210360/","status":"planned","kind":"trial","cancerIcon":"resectable-pdac","sub":"NCT06210360","facets":{"kind":["Trial"],"cancers":["Resectable pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Resectable pancreatic ductal adenocarcinoma","href":"/cancers/resectable-pdac/","tip":"Resectable pancreatic cancer is the minority of pancreatic cancer that the surgeon can remove with clear margins because it has not wrapped around the main arteries or spread. Treatment is an operation, usually a Whipple procedure, followed by six months of combination chemotherapy, which is what turns surgery alone into a real chance of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06888674","name":"Personalized Tumor Neoantigen MRNA Therapy Adjuvant Treatment for Postoperative Pancreatic Cancer.","tldr":"A phase 1/2 trial of gemcitabine, capecitabine and sintilimab in pancreatic cancer, run by Zhejiang University, not yet recruiting.","route":"/trials/nct06888674/","status":"planned","kind":"trial","cancerIcon":"resectable-pdac","sub":"NCT06888674","facets":{"kind":["Trial"],"cancers":["Resectable pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Resectable pancreatic ductal adenocarcinoma","href":"/cancers/resectable-pdac/","tip":"Resectable pancreatic cancer is the minority of pancreatic cancer that the surgeon can remove with clear margins because it has not wrapped around the main arteries or spread. Treatment is an operation, usually a Whipple procedure, followed by six months of combination chemotherapy, which is what turns surgery alone into a real chance of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06888648","name":"Personalized Tumor Neoantigen MRNA Therapy for Advanced Pancreatic Cancer.","tldr":"A phase 1/2 trial of sintilimab in pancreatic cancer, run by Zhejiang University, not yet recruiting.","route":"/trials/nct06888648/","status":"planned","kind":"trial","cancerIcon":"locally-advanced-pdac","sub":"NCT06888648","facets":{"kind":["Trial"],"cancers":["Locally advanced unresectable pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07504263","name":"Phase 1/2a Study of RP-001 in Participants With Advanced Malignancies","tldr":"A phase 1/2 trial in pancreatic cancer, run by Recurv Pharma Inc, not yet recruiting.","route":"/trials/nct07504263/","status":"planned","kind":"trial","cancerIcon":"metastatic-pdac","sub":"NCT07504263","facets":{"kind":["Trial"],"cancers":["Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06030622","name":"Phase 2A Pilot C3 Trial of Recurrent/Refractory Metastatic Advanced Pancreatic Cancer","tldr":"A phase 1/2 trial of gemcitabine in pancreatic cancer, run by State University of New York - Downstate Medical Center, now recruiting.","route":"/trials/nct06030622/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-pdac","sub":"NCT06030622","facets":{"kind":["Trial"],"cancers":["Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06861452","name":"Phase I/IIa Study: RR001 Administered Following Chemotherapy Cycles for Patients With Locally Advanced Pancreatic Carcinoma","tldr":"A phase 1/2 trial in pancreatic cancer, run by EIR Biotherapies s.r.l., now recruiting.","route":"/trials/nct06861452/","status":"recruiting","kind":"trial","cancerIcon":"locally-advanced-pdac","sub":"NCT06861452","facets":{"kind":["Trial"],"cancers":["Locally advanced unresectable pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06454448","name":"Phase Ib/II Clinical Study of Adebrelimab in Combination With Decitabine, Albumin-bound Paclitaxel, and Gemcitabine for the First-line Treatment of Metastatic P","tldr":"A phase 1/2 trial of adebrelimab and decitabine in pancreatic cancer, run by Tianjin Medical University Cancer Institute and Hospital, now recruiting.","route":"/trials/nct06454448/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-pdac","sub":"NCT06454448","facets":{"kind":["Trial"],"cancers":["Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07342725","name":"Phase Ib/II Study to Evaluate the Safety and Efficacy of IBI363 in Combination With Chemotherapy as Second-Line Therapy for Unresectable Locally Advanced or Met","tldr":"A phase 1/2 trial of IBI363 in pancreatic cancer, run by Ruijin Hospital, not yet recruiting.","route":"/trials/nct07342725/","status":"planned","kind":"trial","cancerIcon":"locally-advanced-pdac","sub":"NCT07342725","facets":{"kind":["Trial"],"cancers":["Locally advanced unresectable pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05083247","name":"Preoperative mFOLFIRINOX (or Gem-Nab-P) +/- Isotoxic High-dose SBRT for Borderline Resectable Pancreatic Adenocarcinoma","tldr":"A phase 2 trial in pancreatic cancer, run by Erasme University Hospital, now recruiting.","route":"/trials/nct05083247/","status":"recruiting","kind":"trial","cancerIcon":"borderline-resectable-pdac","sub":"NCT05083247","facets":{"kind":["Trial"],"cancers":["Borderline resectable pancreatic ductal adenocarcinoma","Resectable pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Borderline resectable pancreatic ductal adenocarcinoma","href":"/cancers/borderline-resectable-pdac/","tip":"Borderline resectable pancreatic cancer touches the big blood vessels behind the pancreas, so an operation straight away would probably leave cancer behind. Chemotherapy first, usually FOLFIRINOX for several months and sometimes radiotherapy, shrinks the edge of the tumour, and patients whose disease has not spread go on to surgery with a better chance of a clean removal."},{"label":"Resectable pancreatic ductal adenocarcinoma","href":"/cancers/resectable-pdac/","tip":"Resectable pancreatic cancer is the minority of pancreatic cancer that the surgeon can remove with clear margins because it has not wrapped around the main arteries or spread. Treatment is an operation, usually a Whipple procedure, followed by six months of combination chemotherapy, which is what turns surgery alone into a real chance of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05679583","name":"Preoperative Stereotactic Body Radiation Therapy in Patients With Resectable Pancreatic Cancer","tldr":"A phase 2 trial in pancreatic cancer, run by Yonsei University, now recruiting.","route":"/trials/nct05679583/","status":"recruiting","kind":"trial","cancerIcon":"resectable-pdac","sub":"NCT05679583","facets":{"kind":["Trial"],"cancers":["Resectable pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Resectable pancreatic ductal adenocarcinoma","href":"/cancers/resectable-pdac/","tip":"Resectable pancreatic cancer is the minority of pancreatic cancer that the surgeon can remove with clear margins because it has not wrapped around the main arteries or spread. Treatment is an operation, usually a Whipple procedure, followed by six months of combination chemotherapy, which is what turns surgery alone into a real chance of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07825753","name":"Protein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast Cancer","tldr":"A phase 2 trial of trastuzumab emtansine, trastuzumab deruxtecan, datopotamab deruxtecan, sacituzumab govitecan and other drugs in pancreatic cancer, run by Fudan University, not yet recruiting.","route":"/trials/nct07825753/","status":"planned","kind":"trial","cancerIcon":"locally-advanced-pdac","sub":"NCT07825753","facets":{"kind":["Trial"],"cancers":["Locally advanced unresectable pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct02598349","name":"Proton Radiation for Unresectable, Borderline Resectable, or Medically Inoperable Carcinoma of the Pancreas","tldr":"A phase 2 trial of capecitabine in pancreatic cancer, run by Proton Collaborative Group, now recruiting.","route":"/trials/nct02598349/","status":"recruiting","kind":"trial","cancerIcon":"borderline-resectable-pdac","sub":"NCT02598349","facets":{"kind":["Trial"],"cancers":["Borderline resectable pancreatic ductal adenocarcinoma","Locally advanced unresectable pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Borderline resectable pancreatic ductal adenocarcinoma","href":"/cancers/borderline-resectable-pdac/","tip":"Borderline resectable pancreatic cancer touches the big blood vessels behind the pancreas, so an operation straight away would probably leave cancer behind. Chemotherapy first, usually FOLFIRINOX for several months and sometimes radiotherapy, shrinks the edge of the tumour, and patients whose disease has not spread go on to surgery with a better chance of a clean removal."},{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07269626","name":"PULSAR in Systemic Therapy for Pancreatic Cancer","tldr":"A phase 2 trial in pancreatic cancer, run by Samsung Medical Center, now recruiting.","route":"/trials/nct07269626/","status":"recruiting","kind":"trial","cancerIcon":"borderline-resectable-pdac","sub":"NCT07269626","facets":{"kind":["Trial"],"cancers":["Borderline resectable pancreatic ductal adenocarcinoma","Resectable pancreatic ductal adenocarcinoma","Locally advanced unresectable pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Borderline resectable pancreatic ductal adenocarcinoma","href":"/cancers/borderline-resectable-pdac/","tip":"Borderline resectable pancreatic cancer touches the big blood vessels behind the pancreas, so an operation straight away would probably leave cancer behind. Chemotherapy first, usually FOLFIRINOX for several months and sometimes radiotherapy, shrinks the edge of the tumour, and patients whose disease has not spread go on to surgery with a better chance of a clean removal."},{"label":"Resectable pancreatic ductal adenocarcinoma","href":"/cancers/resectable-pdac/","tip":"Resectable pancreatic cancer is the minority of pancreatic cancer that the surgeon can remove with clear margins because it has not wrapped around the main arteries or spread. Treatment is an operation, usually a Whipple procedure, followed by six months of combination chemotherapy, which is what turns surgery alone into a real chance of cure."},{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04683315","name":"PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples","tldr":"A phase 2 trial in pancreatic cancer, run by Medical College of Wisconsin, now recruiting.","route":"/trials/nct04683315/","status":"recruiting","kind":"trial","cancerIcon":"resectable-pdac","sub":"NCT04683315","facets":{"kind":["Trial"],"cancers":["Resectable pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Resectable pancreatic ductal adenocarcinoma","href":"/cancers/resectable-pdac/","tip":"Resectable pancreatic cancer is the minority of pancreatic cancer that the surgeon can remove with clear margins because it has not wrapped around the main arteries or spread. Treatment is an operation, usually a Whipple procedure, followed by six months of combination chemotherapy, which is what turns surgery alone into a real chance of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06750861","name":"QL1706 Plus Chemotherapy With AG Regime as First-line Treatment of Advanced PDAC","tldr":"A phase 2 trial of iparomlimab and tuvonralimab in pancreatic cancer, run by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, not yet recruiting.","route":"/trials/nct06750861/","status":"planned","kind":"trial","cancerIcon":"locally-advanced-pdac","sub":"NCT06750861","facets":{"kind":["Trial"],"cancers":["Locally advanced unresectable pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06951997","name":"QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer","tldr":"A phase 2 trial of iparomlimab and tuvonralimab, tucidinostat (chidamide), gemcitabine and nab-paclitaxel in pancreatic cancer, run by Tianjin Medical University Cancer Institute and Hospital, now recruiting.","route":"/trials/nct06951997/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-pdac","sub":"NCT06951997","facets":{"kind":["Trial"],"cancers":["Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07110064","name":"QL1706+Lenvatinib+AG Regimen as First-line Treatment for Advanced Metastatic Pancreatic Cancer","tldr":"A phase 2 trial of iparomlimab and tuvonralimab, lenvatinib and gemcitabine + nab-paclitaxel in pancreatic cancer, run by Du Juan, now recruiting.","route":"/trials/nct07110064/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-pdac","sub":"NCT07110064","facets":{"kind":["Trial"],"cancers":["Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06250972","name":"Radiotherapy to Patients With CA19-9-elevated Advanced Pancreatic Cancer","tldr":"A phase 3 trial in pancreatic cancer, run by Fudan University, now recruiting.","route":"/trials/nct06250972/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-pdac","sub":"NCT06250972","facets":{"kind":["Trial"],"cancers":["Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07632118","name":"Radiotherapy With GX Regimen as Adjuvant Therapy for High-risk Patients Following Pancreatic Cancer Surgery","tldr":"A phase 3 trial in pancreatic cancer, run by Tianjin Medical University Cancer Institute and Hospital, now recruiting.","route":"/trials/nct07632118/","status":"recruiting","kind":"trial","cancerIcon":"resectable-pdac","sub":"NCT07632118","facets":{"kind":["Trial"],"cancers":["Resectable pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Resectable pancreatic ductal adenocarcinoma","href":"/cancers/resectable-pdac/","tip":"Resectable pancreatic cancer is the minority of pancreatic cancer that the surgeon can remove with clear margins because it has not wrapped around the main arteries or spread. Treatment is an operation, usually a Whipple procedure, followed by six months of combination chemotherapy, which is what turns surgery alone into a real chance of cure."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06573398","name":"Radiotherapy With Sequential Chemotherapy Combined With PD-1 Inhibitor and Thymalfasin for BRPC","tldr":"A phase 2 trial of tislelizumab in pancreatic cancer, run by Ruijin Hospital, not yet recruiting.","route":"/trials/nct06573398/","status":"planned","kind":"trial","cancerIcon":"borderline-resectable-pdac","sub":"NCT06573398","facets":{"kind":["Trial"],"cancers":["Borderline resectable pancreatic ductal adenocarcinoma","Resectable pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Borderline resectable pancreatic ductal adenocarcinoma","href":"/cancers/borderline-resectable-pdac/","tip":"Borderline resectable pancreatic cancer touches the big blood vessels behind the pancreas, so an operation straight away would probably leave cancer behind. Chemotherapy first, usually FOLFIRINOX for several months and sometimes radiotherapy, shrinks the edge of the tumour, and patients whose disease has not spread go on to surgery with a better chance of a clean removal."},{"label":"Resectable pancreatic ductal adenocarcinoma","href":"/cancers/resectable-pdac/","tip":"Resectable pancreatic cancer is the minority of pancreatic cancer that the surgeon can remove with clear margins because it has not wrapped around the main arteries or spread. Treatment is an operation, usually a Whipple procedure, followed by six months of combination chemotherapy, which is what turns surgery alone into a real chance of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06411795","name":"Rectus Sheath Block With Liposomal Bupivacaine Versus Thoracic Epidural Analgesia for Pain Control Following Pancreatoduodenectomy","tldr":"A phase 2 trial in pancreatic cancer, run by Masonic Cancer Center, University of Minnesota, now recruiting.","route":"/trials/nct06411795/","status":"recruiting","kind":"trial","cancerIcon":"resectable-pdac","sub":"NCT06411795","facets":{"kind":["Trial"],"cancers":["Resectable pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Resectable pancreatic ductal adenocarcinoma","href":"/cancers/resectable-pdac/","tip":"Resectable pancreatic cancer is the minority of pancreatic cancer that the surgeon can remove with clear margins because it has not wrapped around the main arteries or spread. Treatment is an operation, usually a Whipple procedure, followed by six months of combination chemotherapy, which is what turns surgery alone into a real chance of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06756074","name":"Reinforced Pancreaticojejunostomy With or Without glubran2","tldr":"A phase 2 trial in pancreatic cancer, run by Minia University, now recruiting.","route":"/trials/nct06756074/","status":"recruiting","kind":"trial","cancerIcon":"resectable-pdac","sub":"NCT06756074","facets":{"kind":["Trial"],"cancers":["Resectable pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Resectable pancreatic ductal adenocarcinoma","href":"/cancers/resectable-pdac/","tip":"Resectable pancreatic cancer is the minority of pancreatic cancer that the surgeon can remove with clear margins because it has not wrapped around the main arteries or spread. Treatment is an operation, usually a Whipple procedure, followed by six months of combination chemotherapy, which is what turns surgery alone into a real chance of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06580002","name":"Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial","tldr":"A phase 2 trial in pancreatic cancer, run by University of California, Irvine, now recruiting.","route":"/trials/nct06580002/","status":"recruiting","kind":"trial","cancerIcon":"pancreatic","sub":"NCT06580002","facets":{"kind":["Trial"],"cancers":["Pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07814859","name":"Retlirafusp Alfa Combined With Famitinib, Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Unresectable Pancreatic Cancer","tldr":"A phase 2 trial in pancreatic cancer, run by The First Affiliated Hospital of Zhengzhou University, not yet recruiting.","route":"/trials/nct07814859/","status":"planned","kind":"trial","cancerIcon":"locally-advanced-pdac","sub":"NCT07814859","facets":{"kind":["Trial"],"cancers":["Locally advanced unresectable pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07773363","name":"Retlirafusp Alfa Plus Apatinib and Chemotherapy as Second-Line Treatment for Pancreatic Cancer","tldr":"A phase 2 trial of retlirafusp alfa and rivoceranib (apatinib) in pancreatic cancer, run by Tang-Du Hospital, not yet recruiting.","route":"/trials/nct07773363/","status":"planned","kind":"trial","cancerIcon":"locally-advanced-pdac","sub":"NCT07773363","facets":{"kind":["Trial"],"cancers":["Locally advanced unresectable pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07044453","name":"Risk-adapted Adjuvant Chemotherapy Guided by the Tumour Stage for Operated Pancreatic Adenocarcinoma Following Neoadjuvant Chemotherapy With mFOLFIRINOX","tldr":"A phase 2/3 trial in pancreatic cancer, run by University Hospital, Rouen, now recruiting.","route":"/trials/nct07044453/","status":"recruiting","kind":"trial","cancerIcon":"borderline-resectable-pdac","sub":"NCT07044453","facets":{"kind":["Trial"],"cancers":["Borderline resectable pancreatic ductal adenocarcinoma","Resectable pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Borderline resectable pancreatic ductal adenocarcinoma","href":"/cancers/borderline-resectable-pdac/","tip":"Borderline resectable pancreatic cancer touches the big blood vessels behind the pancreas, so an operation straight away would probably leave cancer behind. Chemotherapy first, usually FOLFIRINOX for several months and sometimes radiotherapy, shrinks the edge of the tumour, and patients whose disease has not spread go on to surgery with a better chance of a clean removal."},{"label":"Resectable pancreatic ductal adenocarcinoma","href":"/cancers/resectable-pdac/","tip":"Resectable pancreatic cancer is the minority of pancreatic cancer that the surgeon can remove with clear margins because it has not wrapped around the main arteries or spread. Treatment is an operation, usually a Whipple procedure, followed by six months of combination chemotherapy, which is what turns surgery alone into a real chance of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07586813","name":"Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gastrointestinal Solid Tumors","tldr":"A phase 2 trial of tretinoin (all-trans retinoic acid, ATRA) in pancreatic cancer, run by Peking University People's Hospital, now recruiting.","route":"/trials/nct07586813/","status":"recruiting","kind":"trial","cancerIcon":"pancreatic","sub":"NCT07586813","facets":{"kind":["Trial"],"cancers":["Pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07561463","name":"Sacituzumab Tirumotecan for Pancreatic Cancer","tldr":"A phase 2 trial of sacituzumab tirumotecan in pancreatic cancer, run by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, not yet recruiting.","route":"/trials/nct07561463/","status":"planned","kind":"trial","cancerIcon":"locally-advanced-pdac","sub":"NCT07561463","facets":{"kind":["Trial"],"cancers":["Locally advanced unresectable pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07745790","name":"Safety and Efficacy of Multimodal Thermal Therapy (MTT) Combined With KRAS G12V mRNA Vaccine, S-1, and Sintilimab in Patients With Metastatic Pancreatic Cancer","tldr":"A phase 2 trial of sintilimab and tegafur, gimeracil and oteracil (S-1) in pancreatic cancer, run by Ruijin Hospital, not yet recruiting.","route":"/trials/nct07745790/","status":"planned","kind":"trial","cancerIcon":"metastatic-pdac","sub":"NCT07745790","facets":{"kind":["Trial"],"cancers":["Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07665684","name":"Samuraciclib in Combination With Gemcitabine/Nab-Paclitaxel in Patients With Metastatic Basal-Like Pancreatic Cancer","tldr":"A phase 1/2 trial in pancreatic cancer, run by University Health Network, Toronto, not yet recruiting.","route":"/trials/nct07665684/","status":"planned","kind":"trial","cancerIcon":"metastatic-pdac","sub":"NCT07665684","facets":{"kind":["Trial"],"cancers":["Metastatic pancreatic ductal adenocarcinoma","BRCA or PALB2-mutant pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."},{"label":"BRCA or PALB2-mutant pancreatic ductal adenocarcinoma","href":"/cancers/brca-palb2-pdac/","tip":"BRCA or PALB2-mutant pancreatic cancer is pancreatic cancer in someone who inherited a faulty copy of a gene that repairs broken DNA. These tumours respond better to platinum chemotherapy, and the POLO trial showed that the PARP inhibitor olaparib, taken after platinum has held the disease, delays its return; that made it the first targeted drug approved for a pancreatic cancer subgroup."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06009029","name":"SBRT Combined With Zimberelimab (GLS-010) in Locally Advanced Pancreatic Cancer (SPARK-1 Study)","tldr":"A phase 2 trial of zimberelimab in pancreatic cancer, run by Peking University Third Hospital, not yet recruiting.","route":"/trials/nct06009029/","status":"planned","kind":"trial","cancerIcon":"locally-advanced-pdac","sub":"NCT06009029","facets":{"kind":["Trial"],"cancers":["Locally advanced unresectable pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07683221","name":"SBRT Followed by Ipilimumab N01, Sintilimab, Nab-Paclitaxel and Gemcitabine for Locally Advanced Pancreatic Cancer","tldr":"A phase 2 trial of sintilimab and gemcitabine + nab-paclitaxel in pancreatic cancer, run by Shandong Cancer Hospital and Institute, not yet recruiting.","route":"/trials/nct07683221/","status":"planned","kind":"trial","cancerIcon":"locally-advanced-pdac","sub":"NCT07683221","facets":{"kind":["Trial"],"cancers":["Locally advanced unresectable pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06700603","name":"Second-line Irinotecan Liposome Combination Regimen for Irinotecan-treated Pancreatic Cancer","tldr":"A phase 2 trial of fluorouracil (5-FU) in pancreatic cancer, run by Rui-hua Xu, MD, PhD, not yet recruiting.","route":"/trials/nct06700603/","status":"planned","kind":"trial","cancerIcon":"metastatic-pdac","sub":"NCT06700603","facets":{"kind":["Trial"],"cancers":["Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06166589","name":"Second-line Zimberelimab and SIRIOX Chemotherapy for Patient With Previously AG Chemotherapy Treated Pancreatic Cancer","tldr":"A phase 2 trial of zimberelimab, cAPOX (capecitabine, oxaliplatin), tegafur, gimeracil and oteracil (S-1) and fOLFIRI (5-FU, leucovorin, irinotecan) in pancreatic cancer, run by Shanghai Zhongshan Hospital, not yet recruiting.","route":"/trials/nct06166589/","status":"planned","kind":"trial","cancerIcon":"metastatic-pdac","sub":"NCT06166589","facets":{"kind":["Trial"],"cancers":["Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06946420","name":"SENECA: First Line metaStatic pancrEatic caNcer Primary and Distant (if Oligometastatic) lEsion direCted rAdiotherapy","tldr":"A phase 3 trial in pancreatic cancer, run by Fondazione Policlinico Universitario Agostino Gemelli IRCCS, active but no longer recruiting.","route":"/trials/nct06946420/","status":"active","kind":"trial","cancerIcon":"metastatic-pdac","sub":"NCT06946420","facets":{"kind":["Trial"],"cancers":["Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04570943","name":"Sequential Treatment With GEMBRAX and Then FOLFIRINOX Followed by Stereotactic MRI-guided Radiotherapy in Patients With Locally Advanced Pancreatic Cancer","tldr":"A phase 2 trial in pancreatic cancer, run by Institut du Cancer de Montpellier - Val d'Aurelle, now recruiting.","route":"/trials/nct04570943/","status":"recruiting","kind":"trial","cancerIcon":"locally-advanced-pdac","sub":"NCT04570943","facets":{"kind":["Trial"],"cancers":["Locally advanced unresectable pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06050317","name":"Sintilimab Combined With Chemotherapy and Radiotherapy in Patients With Inoperable Pancreatic Cancer","tldr":"A phase 2 trial in pancreatic cancer, run by Shandong Cancer Hospital and Institute, now recruiting.","route":"/trials/nct06050317/","status":"recruiting","kind":"trial","cancerIcon":"locally-advanced-pdac","sub":"NCT06050317","facets":{"kind":["Trial"],"cancers":["Locally advanced unresectable pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07748611","name":"SMAD4 Tailored Neoadjuvant Therapy for the Treatment of Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma, SMART-PANC Trial","tldr":"A phase 2 trial of fluorouracil (5-FU), gemcitabine, fOLFIRI (5-FU, leucovorin, irinotecan), fLOT (5-FU, leucovorin, oxaliplatin, docetaxel) and other drugs in pancreatic cancer, run by Northwestern University, not yet recruiting.","route":"/trials/nct07748611/","status":"planned","kind":"trial","cancerIcon":"borderline-resectable-pdac","sub":"NCT07748611","facets":{"kind":["Trial"],"cancers":["Borderline resectable pancreatic ductal adenocarcinoma","Resectable pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Borderline resectable pancreatic ductal adenocarcinoma","href":"/cancers/borderline-resectable-pdac/","tip":"Borderline resectable pancreatic cancer touches the big blood vessels behind the pancreas, so an operation straight away would probably leave cancer behind. Chemotherapy first, usually FOLFIRINOX for several months and sometimes radiotherapy, shrinks the edge of the tumour, and patients whose disease has not spread go on to surgery with a better chance of a clean removal."},{"label":"Resectable pancreatic ductal adenocarcinoma","href":"/cancers/resectable-pdac/","tip":"Resectable pancreatic cancer is the minority of pancreatic cancer that the surgeon can remove with clear margins because it has not wrapped around the main arteries or spread. Treatment is an operation, usually a Whipple procedure, followed by six months of combination chemotherapy, which is what turns surgery alone into a real chance of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06714604","name":"Standard or Prolonged Neoadjuvant Chemotherapy Before Surgery for BR/LAPC","tldr":"A phase 3 trial in pancreatic cancer, run by Sahlgrenska University Hospital, now recruiting.","route":"/trials/nct06714604/","status":"recruiting","kind":"trial","cancerIcon":"borderline-resectable-pdac","sub":"NCT06714604","facets":{"kind":["Trial"],"cancers":["Borderline resectable pancreatic ductal adenocarcinoma","Resectable pancreatic ductal adenocarcinoma","Locally advanced unresectable pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Borderline resectable pancreatic ductal adenocarcinoma","href":"/cancers/borderline-resectable-pdac/","tip":"Borderline resectable pancreatic cancer touches the big blood vessels behind the pancreas, so an operation straight away would probably leave cancer behind. Chemotherapy first, usually FOLFIRINOX for several months and sometimes radiotherapy, shrinks the edge of the tumour, and patients whose disease has not spread go on to surgery with a better chance of a clean removal."},{"label":"Resectable pancreatic ductal adenocarcinoma","href":"/cancers/resectable-pdac/","tip":"Resectable pancreatic cancer is the minority of pancreatic cancer that the surgeon can remove with clear margins because it has not wrapped around the main arteries or spread. Treatment is an operation, usually a Whipple procedure, followed by six months of combination chemotherapy, which is what turns surgery alone into a real chance of cure."},{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06259058","name":"Stereotactic Body Radiation Therapy Followed by NALIRIFOX vs NALIRIFOX for Borderline Resectable Pancreatic Cancer","tldr":"A phase 1/2 trial of liposomal irinotecan, cAPOX (capecitabine, oxaliplatin), fluorouracil (5-FU) and fLOT (5-FU, leucovorin, oxaliplatin, docetaxel) in pancreatic cancer, run by Tianjin Medical University Cancer Institute and Hospital, not yet recruiting.","route":"/trials/nct06259058/","status":"planned","kind":"trial","cancerIcon":"borderline-resectable-pdac","sub":"NCT06259058","facets":{"kind":["Trial"],"cancers":["Borderline resectable pancreatic ductal adenocarcinoma","Resectable pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Borderline resectable pancreatic ductal adenocarcinoma","href":"/cancers/borderline-resectable-pdac/","tip":"Borderline resectable pancreatic cancer touches the big blood vessels behind the pancreas, so an operation straight away would probably leave cancer behind. Chemotherapy first, usually FOLFIRINOX for several months and sometimes radiotherapy, shrinks the edge of the tumour, and patients whose disease has not spread go on to surgery with a better chance of a clean removal."},{"label":"Resectable pancreatic ductal adenocarcinoma","href":"/cancers/resectable-pdac/","tip":"Resectable pancreatic cancer is the minority of pancreatic cancer that the surgeon can remove with clear margins because it has not wrapped around the main arteries or spread. Treatment is an operation, usually a Whipple procedure, followed by six months of combination chemotherapy, which is what turns surgery alone into a real chance of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07126158","name":"Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma","tldr":"A phase 2 trial of avutometinib + defactinib in pancreatic cancer, run by Washington University School of Medicine, now recruiting.","route":"/trials/nct07126158/","status":"recruiting","kind":"trial","cancerIcon":"borderline-resectable-pdac","sub":"NCT07126158","facets":{"kind":["Trial"],"cancers":["Borderline resectable pancreatic ductal adenocarcinoma","Resectable pancreatic ductal adenocarcinoma","Locally advanced unresectable pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Borderline resectable pancreatic ductal adenocarcinoma","href":"/cancers/borderline-resectable-pdac/","tip":"Borderline resectable pancreatic cancer touches the big blood vessels behind the pancreas, so an operation straight away would probably leave cancer behind. Chemotherapy first, usually FOLFIRINOX for several months and sometimes radiotherapy, shrinks the edge of the tumour, and patients whose disease has not spread go on to surgery with a better chance of a clean removal."},{"label":"Resectable pancreatic ductal adenocarcinoma","href":"/cancers/resectable-pdac/","tip":"Resectable pancreatic cancer is the minority of pancreatic cancer that the surgeon can remove with clear margins because it has not wrapped around the main arteries or spread. Treatment is an operation, usually a Whipple procedure, followed by six months of combination chemotherapy, which is what turns surgery alone into a real chance of cure."},{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05241249","name":"Stimulation With Bethanechol in Combination With Gemcitabine and Nab-paclitaxel in Pancreatic Adenocarcinoma","tldr":"A phase 2 trial of gemcitabine and nab-paclitaxel in pancreatic cancer, run by Susan E. Bates, now recruiting.","route":"/trials/nct05241249/","status":"recruiting","kind":"trial","cancerIcon":"borderline-resectable-pdac","sub":"NCT05241249","facets":{"kind":["Trial"],"cancers":["Borderline resectable pancreatic ductal adenocarcinoma","Resectable pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Borderline resectable pancreatic ductal adenocarcinoma","href":"/cancers/borderline-resectable-pdac/","tip":"Borderline resectable pancreatic cancer touches the big blood vessels behind the pancreas, so an operation straight away would probably leave cancer behind. Chemotherapy first, usually FOLFIRINOX for several months and sometimes radiotherapy, shrinks the edge of the tumour, and patients whose disease has not spread go on to surgery with a better chance of a clean removal."},{"label":"Resectable pancreatic ductal adenocarcinoma","href":"/cancers/resectable-pdac/","tip":"Resectable pancreatic cancer is the minority of pancreatic cancer that the surgeon can remove with clear margins because it has not wrapped around the main arteries or spread. Treatment is an operation, usually a Whipple procedure, followed by six months of combination chemotherapy, which is what turns surgery alone into a real chance of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07483983","name":"Study Investigating ASP3082 in Patients With Metastatic/Locally Advanced Non-small-cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC), With Bi","tldr":"A phase 2 trial of setidegrasib in pancreatic cancer, run by Gustave Roussy, Cancer Campus, Grand Paris, now recruiting.","route":"/trials/nct07483983/","status":"recruiting","kind":"trial","cancerIcon":"locally-advanced-pdac","sub":"NCT07483983","facets":{"kind":["Trial"],"cancers":["Locally advanced unresectable pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06722911","name":"Study of Adjuvant Nimotuzumab Combined with Nab-paclitaxel+ Gemcitabine in EGFR-positive Pancreatic Cancer","tldr":"A phase 2 trial of nimotuzumab in pancreatic cancer, run by Zhejiang Provincial People's Hospital, now recruiting.","route":"/trials/nct06722911/","status":"recruiting","kind":"trial","cancerIcon":"resectable-pdac","sub":"NCT06722911","facets":{"kind":["Trial"],"cancers":["Resectable pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Resectable pancreatic ductal adenocarcinoma","href":"/cancers/resectable-pdac/","tip":"Resectable pancreatic cancer is the minority of pancreatic cancer that the surgeon can remove with clear margins because it has not wrapped around the main arteries or spread. Treatment is an operation, usually a Whipple procedure, followed by six months of combination chemotherapy, which is what turns surgery alone into a real chance of cure."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05776524","name":"Study of Amplitude-Modulated Radiofrequency Electromagnetic Fields in Metastatic Pancreatic Cancer","tldr":"A phase 2 trial of nab-paclitaxel and gemcitabine in pancreatic cancer, run by THERABIONIC INC., now recruiting.","route":"/trials/nct05776524/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-pdac","sub":"NCT05776524","facets":{"kind":["Trial"],"cancers":["Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07435038","name":"Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS","tldr":"A phase 1/2 trial in pancreatic cancer, run by Betta Pharmaceuticals Co., Ltd., now recruiting.","route":"/trials/nct07435038/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-pdac","sub":"NCT07435038","facets":{"kind":["Trial"],"cancers":["Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04195347","name":"Study of CM4620 to Reduce the Severity of Pancreatitis Due to Asparaginase","tldr":"A phase 1/2 trial in pancreatic cancer, run by St. Jude Children's Research Hospital, now recruiting.","route":"/trials/nct04195347/","status":"recruiting","kind":"trial","cancerIcon":"pancreatic","sub":"NCT04195347","facets":{"kind":["Trial"],"cancers":["Pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06479239","name":"Study of EGFRBi Armed Fresh PBMC in Metastatic or Unresectable Pancreatic Cancer","tldr":"A phase 1/2 trial in pancreatic cancer, run by University of Virginia, now recruiting.","route":"/trials/nct06479239/","status":"recruiting","kind":"trial","cancerIcon":"locally-advanced-pdac","sub":"NCT06479239","facets":{"kind":["Trial"],"cancers":["Locally advanced unresectable pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06783140","name":"Study of NABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Pancreatic Cancer","tldr":"A phase 2/3 trial of nab-paclitaxel, gemcitabine and cisplatin in pancreatic cancer, run by University Health Network, Toronto, active but no longer recruiting.","route":"/trials/nct06783140/","status":"active","kind":"trial","cancerIcon":"metastatic-pdac","sub":"NCT06783140","facets":{"kind":["Trial"],"cancers":["Metastatic pancreatic ductal adenocarcinoma","BRCA or PALB2-mutant pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."},{"label":"BRCA or PALB2-mutant pancreatic ductal adenocarcinoma","href":"/cancers/brca-palb2-pdac/","tip":"BRCA or PALB2-mutant pancreatic cancer is pancreatic cancer in someone who inherited a faulty copy of a gene that repairs broken DNA. These tumours respond better to platinum chemotherapy, and the POLO trial showed that the PARP inhibitor olaparib, taken after platinum has held the disease, delays its return; that made it the first targeted drug approved for a pancreatic cancer subgroup."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06998940","name":"Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations","tldr":"A phase 3 trial of fluorouracil (5-FU), gemcitabine, fOLFIRI (5-FU, leucovorin, irinotecan), fLOT (5-FU, leucovorin, oxaliplatin, docetaxel) and other drugs in pancreatic cancer, run by SWOG Cancer Research Network, now recruiting.","route":"/trials/nct06998940/","status":"recruiting","kind":"trial","cancerIcon":"locally-advanced-pdac","sub":"NCT06998940","facets":{"kind":["Trial"],"cancers":["Locally advanced unresectable pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma","KRAS wild-type pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."},{"label":"KRAS wild-type pancreatic ductal adenocarcinoma","href":"/cancers/kras-wild-type-pdac/","tip":"KRAS wild-type pancreatic cancer is the one in ten pancreatic cancers without the KRAS mutation that drives the rest. Instead many carry a different switched-on gene, often a fusion involving NRG1, NTRK, ALK, ROS1, FGFR2 or RET, or a BRAF change, and several of these have approved pills or antibodies, so these tumours must be sequenced with a test that detects fusions."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05988372","name":"Surufatinib and Serplulimab Combined With AG Regimen Compare With AG Regimen as Conversion Therapy for Patients With Locally Advanced Pancreatic Cancer (SAGE)","tldr":"A phase 2 trial of surufatinib, serplulimab and gemcitabine in pancreatic cancer, run by Sun Yat-sen University, not yet recruiting.","route":"/trials/nct05988372/","status":"planned","kind":"trial","cancerIcon":"locally-advanced-pdac","sub":"NCT05988372","facets":{"kind":["Trial"],"cancers":["Locally advanced unresectable pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06361030","name":"Surufatinib Combined With Gemcitabine Plus Nab-paclitaxel in Locally Advanced Pancreatic Cancer","tldr":"A phase 2 trial in pancreatic cancer, run by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, not yet recruiting.","route":"/trials/nct06361030/","status":"planned","kind":"trial","cancerIcon":"locally-advanced-pdac","sub":"NCT06361030","facets":{"kind":["Trial"],"cancers":["Locally advanced unresectable pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07833241","name":"Surufatinib in Combination With Iparomlimab and Tuvonralimab Injection and AG Chemotherapy for Neoadjuvant Therapy of HRPC or BRPC","tldr":"A phase 2 trial of gemcitabine + nab-paclitaxel, gemcitabine, capecitabine and fOLFIRINOX / mFOLFIRINOX in pancreatic cancer, run by Shanghai Zhongshan Hospital, not yet recruiting.","route":"/trials/nct07833241/","status":"planned","kind":"trial","cancerIcon":"borderline-resectable-pdac","sub":"NCT07833241","facets":{"kind":["Trial"],"cancers":["Borderline resectable pancreatic ductal adenocarcinoma","Resectable pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Borderline resectable pancreatic ductal adenocarcinoma","href":"/cancers/borderline-resectable-pdac/","tip":"Borderline resectable pancreatic cancer touches the big blood vessels behind the pancreas, so an operation straight away would probably leave cancer behind. Chemotherapy first, usually FOLFIRINOX for several months and sometimes radiotherapy, shrinks the edge of the tumour, and patients whose disease has not spread go on to surgery with a better chance of a clean removal."},{"label":"Resectable pancreatic ductal adenocarcinoma","href":"/cancers/resectable-pdac/","tip":"Resectable pancreatic cancer is the minority of pancreatic cancer that the surgeon can remove with clear margins because it has not wrapped around the main arteries or spread. Treatment is an operation, usually a Whipple procedure, followed by six months of combination chemotherapy, which is what turns surgery alone into a real chance of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05218889","name":"Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer","tldr":"A phase 1/2 trial of gemcitabine + nab-paclitaxel in pancreatic cancer, run by Chinese PLA General Hospital, now recruiting.","route":"/trials/nct05218889/","status":"recruiting","kind":"trial","cancerIcon":"locally-advanced-pdac","sub":"NCT05218889","facets":{"kind":["Trial"],"cancers":["Locally advanced unresectable pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07436741","name":"Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for High - Risk Resectable or Borderline Resectable P","tldr":"A phase 3 trial of gemcitabine + nab-paclitaxel in pancreatic cancer, run by Tianjin Medical University Cancer Institute and Hospital, now recruiting.","route":"/trials/nct07436741/","status":"recruiting","kind":"trial","cancerIcon":"borderline-resectable-pdac","sub":"NCT07436741","facets":{"kind":["Trial"],"cancers":["Borderline resectable pancreatic ductal adenocarcinoma","Resectable pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Borderline resectable pancreatic ductal adenocarcinoma","href":"/cancers/borderline-resectable-pdac/","tip":"Borderline resectable pancreatic cancer touches the big blood vessels behind the pancreas, so an operation straight away would probably leave cancer behind. Chemotherapy first, usually FOLFIRINOX for several months and sometimes radiotherapy, shrinks the edge of the tumour, and patients whose disease has not spread go on to surgery with a better chance of a clean removal."},{"label":"Resectable pancreatic ductal adenocarcinoma","href":"/cancers/resectable-pdac/","tip":"Resectable pancreatic cancer is the minority of pancreatic cancer that the surgeon can remove with clear margins because it has not wrapped around the main arteries or spread. Treatment is an operation, usually a Whipple procedure, followed by six months of combination chemotherapy, which is what turns surgery alone into a real chance of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07469956","name":"Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic Cancer","tldr":"A phase 2 trial of surufatinib, toripalimab and fOLFIRINOX / mFOLFIRINOX in pancreatic cancer, run by Sun Yat-sen University, not yet recruiting.","route":"/trials/nct07469956/","status":"planned","kind":"trial","cancerIcon":"borderline-resectable-pdac","sub":"NCT07469956","facets":{"kind":["Trial"],"cancers":["Borderline resectable pancreatic ductal adenocarcinoma","Resectable pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Borderline resectable pancreatic ductal adenocarcinoma","href":"/cancers/borderline-resectable-pdac/","tip":"Borderline resectable pancreatic cancer touches the big blood vessels behind the pancreas, so an operation straight away would probably leave cancer behind. Chemotherapy first, usually FOLFIRINOX for several months and sometimes radiotherapy, shrinks the edge of the tumour, and patients whose disease has not spread go on to surgery with a better chance of a clean removal."},{"label":"Resectable pancreatic ductal adenocarcinoma","href":"/cancers/resectable-pdac/","tip":"Resectable pancreatic cancer is the minority of pancreatic cancer that the surgeon can remove with clear margins because it has not wrapped around the main arteries or spread. Treatment is an operation, usually a Whipple procedure, followed by six months of combination chemotherapy, which is what turns surgery alone into a real chance of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06914674","name":"Tamoxifen for Advanced Solid Pseudopapillary Tumor of the Pancreas","tldr":"A phase 2 trial in pancreatic cancer, run by Fudan University, now recruiting.","route":"/trials/nct06914674/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-pdac","sub":"NCT06914674","facets":{"kind":["Trial"],"cancers":["Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04851119","name":"Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors","tldr":"A phase 1/2 trial in pancreatic cancer, run by Children's Oncology Group, now recruiting.","route":"/trials/nct04851119/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-pdac","sub":"NCT04851119","facets":{"kind":["Trial"],"cancers":["Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05836870","name":"Tele-PancFit: A Multi-site Trial of Video-based Strengthening Exercise Prehabilitation for Patients With Resectable Pancreatic Cancer","tldr":"A phase 3 trial in pancreatic cancer, run by M.D. Anderson Cancer Center, active but no longer recruiting.","route":"/trials/nct05836870/","status":"active","kind":"trial","cancerIcon":"borderline-resectable-pdac","sub":"NCT05836870","facets":{"kind":["Trial"],"cancers":["Borderline resectable pancreatic ductal adenocarcinoma","Resectable pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Borderline resectable pancreatic ductal adenocarcinoma","href":"/cancers/borderline-resectable-pdac/","tip":"Borderline resectable pancreatic cancer touches the big blood vessels behind the pancreas, so an operation straight away would probably leave cancer behind. Chemotherapy first, usually FOLFIRINOX for several months and sometimes radiotherapy, shrinks the edge of the tumour, and patients whose disease has not spread go on to surgery with a better chance of a clean removal."},{"label":"Resectable pancreatic ductal adenocarcinoma","href":"/cancers/resectable-pdac/","tip":"Resectable pancreatic cancer is the minority of pancreatic cancer that the surgeon can remove with clear margins because it has not wrapped around the main arteries or spread. Treatment is an operation, usually a Whipple procedure, followed by six months of combination chemotherapy, which is what turns surgery alone into a real chance of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05053971","name":"Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors","tldr":"A phase 1/2 trial in pancreatic cancer, run by National Cancer Institute (NCI), now recruiting.","route":"/trials/nct05053971/","status":"recruiting","kind":"trial","cancerIcon":"locally-advanced-pdac","sub":"NCT05053971","facets":{"kind":["Trial"],"cancers":["Locally advanced unresectable pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06958328","name":"Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer","tldr":"A phase 3 trial of capecitabine, fluorouracil (5-FU), gemcitabine, irinotecan (and liposomal irinotecan) and other drugs in pancreatic cancer, run by NRG Oncology, now recruiting.","route":"/trials/nct06958328/","status":"recruiting","kind":"trial","cancerIcon":"locally-advanced-pdac","sub":"NCT06958328","facets":{"kind":["Trial"],"cancers":["Locally advanced unresectable pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04172532","name":"Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer","tldr":"A phase 1/2 trial in pancreatic cancer, run by National Cancer Institute (NCI), now recruiting.","route":"/trials/nct04172532/","status":"recruiting","kind":"trial","cancerIcon":"locally-advanced-pdac","sub":"NCT04172532","facets":{"kind":["Trial"],"cancers":["Locally advanced unresectable pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07619521","name":"Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a (Trastuzumab Deruxtecan), for Advanced Pancreatic Ductal Adenocarcinoma","tldr":"A phase 1/2 trial of selumetinib and trastuzumab deruxtecan in pancreatic cancer, run by National Cancer Institute (NCI), now recruiting.","route":"/trials/nct07619521/","status":"recruiting","kind":"trial","cancerIcon":"locally-advanced-pdac","sub":"NCT07619521","facets":{"kind":["Trial"],"cancers":["Locally advanced unresectable pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03492671","name":"Testing the Combination of Two Approved Chemotherapy Drugs and Radiation Prior to Surgery in Localized Pancreatic Cancer","tldr":"A phase 2 trial of nab-paclitaxel in pancreatic cancer, run by Loma Linda University, now recruiting.","route":"/trials/nct03492671/","status":"recruiting","kind":"trial","cancerIcon":"resectable-pdac","sub":"NCT03492671","facets":{"kind":["Trial"],"cancers":["Resectable pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Resectable pancreatic ductal adenocarcinoma","href":"/cancers/resectable-pdac/","tip":"Resectable pancreatic cancer is the minority of pancreatic cancer that the surgeon can remove with clear margins because it has not wrapped around the main arteries or spread. Treatment is an operation, usually a Whipple procedure, followed by six months of combination chemotherapy, which is what turns surgery alone into a real chance of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06017284","name":"Thalidomide to Chemotherapy Related Nausea and Vomiting in Pancreatic Cancer","tldr":"A phase 3 trial of thalidomide, nab-paclitaxel and gemcitabine in pancreatic cancer, run by Fudan University, now recruiting.","route":"/trials/nct06017284/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-pdac","sub":"NCT06017284","facets":{"kind":["Trial"],"cancers":["Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07285044","name":"The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients","tldr":"A phase 2 trial in pancreatic cancer, run by Mayo Clinic, now recruiting.","route":"/trials/nct07285044/","status":"recruiting","kind":"trial","cancerIcon":"pancreatic","sub":"NCT07285044","facets":{"kind":["Trial"],"cancers":["Pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct02000089","name":"The Cancer of the Pancreas Screening-5 CAPS5)Study","tldr":"A phase 3 trial in pancreatic cancer, run by Johns Hopkins University, now recruiting.","route":"/trials/nct02000089/","status":"recruiting","kind":"trial","cancerIcon":"pancreatic","sub":"NCT02000089","facets":{"kind":["Trial"],"cancers":["Pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06843551","name":"The Miami \"EMPIRE\" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-Radiation","tldr":"A phase 2 trial of botensilimab and balstilimab in pancreatic cancer, run by Benjamin Spieler, now recruiting.","route":"/trials/nct06843551/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-pdac","sub":"NCT06843551","facets":{"kind":["Trial"],"cancers":["Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06115499","name":"The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer","tldr":"A phase 2/3 trial of nab-paclitaxel, gemcitabine and cisplatin in pancreatic cancer, run by Alliance for Clinical Trials in Oncology, active but no longer recruiting.","route":"/trials/nct06115499/","status":"active","kind":"trial","cancerIcon":"metastatic-pdac","sub":"NCT06115499","facets":{"kind":["Trial"],"cancers":["Metastatic pancreatic ductal adenocarcinoma","BRCA or PALB2-mutant pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."},{"label":"BRCA or PALB2-mutant pancreatic ductal adenocarcinoma","href":"/cancers/brca-palb2-pdac/","tip":"BRCA or PALB2-mutant pancreatic cancer is pancreatic cancer in someone who inherited a faulty copy of a gene that repairs broken DNA. These tumours respond better to platinum chemotherapy, and the POLO trial showed that the PARP inhibitor olaparib, taken after platinum has held the disease, delays its return; that made it the first targeted drug approved for a pancreatic cancer subgroup."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06946901","name":"The Safety and Effectiveness of Hyperthermic Intraperitoneal Chemotherapy Combined With Intravenous Chemotherapy for Peritoneal Metastatic Pancreatic Cancer, a","tldr":"A phase 2 trial of cisplatin in pancreatic cancer, run by Shanghai Zhongshan Hospital, now recruiting.","route":"/trials/nct06946901/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-pdac","sub":"NCT06946901","facets":{"kind":["Trial"],"cancers":["Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06332274","name":"tislelizUMaB in canceR Patients With molEcuLar residuaL Disease","tldr":"A phase 3 trial of tislelizumab in pancreatic cancer, run by Gustave Roussy, Cancer Campus, Grand Paris, now recruiting.","route":"/trials/nct06332274/","status":"recruiting","kind":"trial","cancerIcon":"pancreatic","sub":"NCT06332274","facets":{"kind":["Trial"],"cancers":["Pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07155525","name":"Tissue Adhesive Glue Modified Cyanoacrylate (Glubran® 2) in Soft Pancreas","tldr":"A phase 3 trial in pancreatic cancer, run by Minia University, now recruiting.","route":"/trials/nct07155525/","status":"recruiting","kind":"trial","cancerIcon":"resectable-pdac","sub":"NCT07155525","facets":{"kind":["Trial"],"cancers":["Resectable pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Resectable pancreatic ductal adenocarcinoma","href":"/cancers/resectable-pdac/","tip":"Resectable pancreatic cancer is the minority of pancreatic cancer that the surgeon can remove with clear margins because it has not wrapped around the main arteries or spread. Treatment is an operation, usually a Whipple procedure, followed by six months of combination chemotherapy, which is what turns surgery alone into a real chance of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03755739","name":"Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors","tldr":"A phase 2/3 trial in pancreatic cancer, run by Second Affiliated Hospital of Guangzhou Medical University, now recruiting.","route":"/trials/nct03755739/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-pdac","sub":"NCT03755739","facets":{"kind":["Trial"],"cancers":["Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06196788","name":"Transcatheter Arterial Infusion to Patients With Advanced Pancreatic Cancer","tldr":"A phase 2 trial of gemcitabine and nab-paclitaxel in pancreatic cancer, run by Fudan University, now recruiting.","route":"/trials/nct06196788/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-pdac","sub":"NCT06196788","facets":{"kind":["Trial"],"cancers":["Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05988814","name":"Trial Evaluating the Efficacy and the Safety of FOLFIRINOX3 Treatment in Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer in First Li","tldr":"A phase 2 trial in pancreatic cancer, run by Centre Georges Francois Leclerc, now recruiting.","route":"/trials/nct05988814/","status":"recruiting","kind":"trial","cancerIcon":"locally-advanced-pdac","sub":"NCT05988814","facets":{"kind":["Trial"],"cancers":["Locally advanced unresectable pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07689539","name":"Trial of DN022150 Versus Chemotherapy in Previously Treated Advanced Pancreatic Cancer With KRAS G12D Mutation","tldr":"A phase 3 trial in pancreatic cancer, run by Jiangxi Kvvit Pharmaceutical Co., Ltd., not yet recruiting.","route":"/trials/nct07689539/","status":"planned","kind":"trial","cancerIcon":"metastatic-pdac","sub":"NCT07689539","facets":{"kind":["Trial"],"cancers":["Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05187338","name":"Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors","tldr":"A phase 1/2 trial of ipilimumab, pembrolizumab and durvalumab in pancreatic cancer, run by Second Affiliated Hospital of Guangzhou Medical University, now recruiting.","route":"/trials/nct05187338/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-pdac","sub":"NCT05187338","facets":{"kind":["Trial"],"cancers":["Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07284277","name":"TTFields and Chemotherapy in Metastatic Pancreatic Adenocarcinoma (mPDAC)","tldr":"A phase 1/2 trial in pancreatic cancer, run by Clinica Universidad de Navarra, Universidad de Navarra, now recruiting.","route":"/trials/nct07284277/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-pdac","sub":"NCT07284277","facets":{"kind":["Trial"],"cancers":["Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03977233","name":"Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer","tldr":"A phase 2 trial of cAPOX (capecitabine, oxaliplatin), fLOT (5-FU, leucovorin, oxaliplatin, docetaxel), irinotecan (and liposomal irinotecan) and fluorouracil (5-FU) in pancreatic cancer, run by UNC Lineberger Comprehensive Cancer Center, now recruiting.","route":"/trials/nct03977233/","status":"recruiting","kind":"trial","cancerIcon":"locally-advanced-pdac","sub":"NCT03977233","facets":{"kind":["Trial"],"cancers":["Locally advanced unresectable pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06813079","name":"Using Tumor Models to Determine Treatments","tldr":"A phase 2 trial of cobimetinib, ponatinib, brigatinib, selinexor and other drugs in pancreatic cancer, run by University Health Network, Toronto, now recruiting.","route":"/trials/nct06813079/","status":"recruiting","kind":"trial","cancerIcon":"locally-advanced-pdac","sub":"NCT06813079","facets":{"kind":["Trial"],"cancers":["Locally advanced unresectable pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05821556","name":"Valproic Acid/Simvastatin Plus Gemcitabine/Nab-paclitaxel Based Regimens in Untreated Metastatic Pancreatic Adenocarcinoma Patients","tldr":"A phase 2 trial of nab-paclitaxel, cisplatin and capecitabine in pancreatic cancer, run by National Cancer Institute, Naples, now recruiting.","route":"/trials/nct05821556/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-pdac","sub":"NCT05821556","facets":{"kind":["Trial"],"cancers":["Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07765836","name":"Vilastobart+Retifanlimab in BRCA or PALB2 Deficient PC","tldr":"A phase 2 trial of retifanlimab in pancreatic cancer, run by Massachusetts General Hospital, not yet recruiting.","route":"/trials/nct07765836/","status":"planned","kind":"trial","cancerIcon":"metastatic-pdac","sub":"NCT07765836","facets":{"kind":["Trial"],"cancers":["Metastatic pancreatic ductal adenocarcinoma","BRCA or PALB2-mutant pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."},{"label":"BRCA or PALB2-mutant pancreatic ductal adenocarcinoma","href":"/cancers/brca-palb2-pdac/","tip":"BRCA or PALB2-mutant pancreatic cancer is pancreatic cancer in someone who inherited a faulty copy of a gene that repairs broken DNA. These tumours respond better to platinum chemotherapy, and the POLO trial showed that the PARP inhibitor olaparib, taken after platinum has held the disease, delays its return; that made it the first targeted drug approved for a pancreatic cancer subgroup."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06601283","name":"Vitamin C Plus Cordyceps to Chemotherapy Related Anemia in Pancreatic Cancer","tldr":"A phase 2/3 trial in pancreatic cancer, run by Fudan University, now recruiting.","route":"/trials/nct06601283/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-pdac","sub":"NCT06601283","facets":{"kind":["Trial"],"cancers":["Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06598033","name":"Vitamin C Plus Cordyceps to Quality of Life in Patients With Terminal Stage Pancreatic Cancer","tldr":"A phase 2/3 trial in pancreatic cancer, run by Fudan University, now recruiting.","route":"/trials/nct06598033/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-pdac","sub":"NCT06598033","facets":{"kind":["Trial"],"cancers":["Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06662669","name":"YL-13027 and/or HY-0102 Combined With AG Regimen Chemotherapy for Metastatic Pancreatic Cancer","tldr":"A phase 1/2 trial of gemcitabine and nab-paclitaxel in pancreatic cancer, run by Shanghai YingLi Pharmaceutical Co. Ltd., not yet recruiting.","route":"/trials/nct06662669/","status":"planned","kind":"trial","cancerIcon":"metastatic-pdac","sub":"NCT06662669","facets":{"kind":["Trial"],"cancers":["Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}}]